

# Notes

<sup>1</sup> World Bank Data.

<sup>2</sup> Reuters (2016) “Brazilian Economy’s Steep Slide Raises Specter Of Depression”, 16/3/2016, <http://www.reuters.com/article/us-brazil-economy-gdp-idUSKCN0W51CZ>

<sup>3</sup> Ibid.

<sup>4</sup> Klaus Schwab/World Economic Forum (2015), “The Global Competitiveness Report 2015-2016”, September 2015.

<sup>5</sup> Economist Intelligence Unit (2015), “Brazil Country Report”, p.7, 08/2015.

<sup>6</sup> Ibid.

<sup>7</sup> Portal Brazil (2016), “Dilma Sanctions Legal Framework for Science, Technology and Innovation”, 1/11/2016, <http://www.brasil.gov.br/governo/2016/01/dilma-sanciona-marco-legal-da-ciencia-tecnologia-e-inovacao-1>

<sup>8</sup> Embassy of Brazil in London (2016), “New Brazilian Legal Framework for Science, Technology and Innovation”, 4/22/2016, [http://londres.itamaraty.gov.br/en-us/legal\\_framework\\_for\\_science,\\_technology\\_&\\_innovation.xml](http://londres.itamaraty.gov.br/en-us/legal_framework_for_science,_technology_&_innovation.xml)

<sup>9</sup> Mattos Filho, Veiga Filho, Marrey Jr e Quiroga Advogados (2015), “Federal Law N° 13.123/2015 - New Legal Framework Concerning Brazilian Biodiversity”, 6/19/2015, <http://www.lexology.com/library/detail.aspx?g=17a10533-609f-4023-9736-75b1deedc55e>

<sup>10</sup> Moeller IP Advisors (2015), “Brazilian President Signs New Biodiversity Law”, 6/23/2015, <http://www.moellerip.com/brazilian-president-signs-new-biodiversity-law/>

<sup>11</sup> Text available at [http://www.planalto.gov.br/ccivil\\_03/Consulta\\_Publica/consultapatrimonioidsp%20.htm#anexo](http://www.planalto.gov.br/ccivil_03/Consulta_Publica/consultapatrimonioidsp%20.htm#anexo)

<sup>12</sup> IHS Life Sciences Blog (2015), “Transforming the Brazilian Domestic Pharma Industry through PDPs”, 07/23/2015, <http://blog.ihs.com/transforming-the-brazilian-domestic-pharma-industry-through-pdps>

<sup>13</sup> Pedro Bernardo/Interfarma (2015), “Presentation to the Lower Chamber”, December 2015, <http://www2.camara.leg.br/atividade-legislativa/comissoes/comissoes-permanentes/cssf/audiencias-publicas/audiencia-publica-2015/audiencia-03.12/apresentacao-interfarma>

<sup>14</sup> Valor Economico (2015), “Innovation Pulse”(translated), 8/14/2015.

<sup>15</sup> BMI (2016), “Brazil Pharmaceuticals and Healthcare Report”, April 2016, <http://store.bmiresearch.com/brazil-pharmaceuticals-healthcare-report.html>

<sup>16</sup> Biopharma Report (2015), “Filgrastim Biosimilar is First Latin Copy Biologic, says Brazil”, 11/24/2015, <http://www.biopharma-reporter.com/Markets-Regulations/Filgrastim-biosimilar-is-first-Latin-copy-biologic-says-Brazil>

<sup>17</sup> Financial Times (2016).

<sup>18</sup> Ibid.

<sup>19</sup> US State Department (2013), “2013 Investment Climate Statement – Brazil”, February 2013.

<sup>20</sup> Ibid.

<sup>21</sup> Iain M. Cockburn, Jean O. Lanjouw, Mark Schankerman (2014) “Patents and the Global Diffusion of New Drugs”, NBER Working Paper No. 20492, Table A2, p. 43.

<sup>22</sup> Pugatch Consilium (2016), “Measuring The Global Biomedical Pulse The Biopharmaceutical Investment & Competitiveness (Bci) Survey – 2016”.

<sup>23</sup> ISAAA Brief 2015, Executive Summary (accessed May 2016), <http://www.isaaa.org/resources/publications/briefs/51/executivesummary/default.asp>

<sup>24</sup> ISAAA Brief 51-2015: Executive Summary.

<sup>25</sup> USDA (2015), “Brazil Agricultural Biotechnology Report”, 7/8/2015, [http://gain.fas.usda.gov/Recent%20GAIN%20Publications/Agricultural%20Biotechnology%20Annual\\_Brasilia\\_Brazil\\_7-8-2015.pdf](http://gain.fas.usda.gov/Recent%20GAIN%20Publications/Agricultural%20Biotechnology%20Annual_Brasilia_Brazil_7-8-2015.pdf)

<sup>26</sup> P. Correa and C. Schmidt (2014), “Public Research Organizations and Agricultural Development in Brazil: How Did Embrapa Get It Right?”, *Economic Premise*, World Bank June 2014, Number 145, p. 1.

<sup>27</sup> B3CNewsWire (2015), “FuturaGene’s Eucalyptus Is Approved for Commercial Use in Brazil”, 4/10/2015, <http://www.b3cnews.com/201504101194/futuragenes-eucalyptus-is-approved-for-commercial-use-in-brazil.html>; Biofuels Digest (2015), “EMBRAPA, FuturaGene signs Eucalyptus Development Deal”, 11/29/2012, <http://www.biofuelsdigest.com/bdigest/2012/11/29/embrapa-futuregene-sign-eucalyptus-development-deal/>

<sup>28</sup> USDA (2015a), “Biofuels Report”, 8/10/2015, [http://gain.fas.usda.gov/Recent%20GAIN%20Publications/Biofuels%20Annual\\_Sao%20Paulo%20ATO\\_Brazil\\_8-4-2015.pdf](http://gain.fas.usda.gov/Recent%20GAIN%20Publications/Biofuels%20Annual_Sao%20Paulo%20ATO_Brazil_8-4-2015.pdf)

<sup>29</sup> Ibid., p.9.

<sup>30</sup> Ibid., p.3.

<sup>31</sup> Biofuels Digest (2016), “Brazilian House Approves Bill to Boost Biodiesel Blend to 10% in Three Years”, 3/3/2016, <http://www.biofuelsdigest.com/bdigest/2016/03/03/brazilian-house-approves-bill-to-boost-biodiesel-blend-to-10-in-three-years/>

<sup>32</sup> Ibid.

<sup>33</sup> Times Higher Education World University Rankings 2015-2016.

- <sup>34</sup> Ibid. Life Sciences.
- <sup>35</sup> World Bank, Data bank, Scientific and technical journal articles, IP.JRN.ARTC.SC. “Scientific and technical journal articles refer to the number of scientific and engineering articles published in the following fields: physics, biology, chemistry, mathematics, clinical medicine, biomedical research, engineering and technology, and earth and space sciences.”
- <sup>36</sup> OECD (2015), Science, Technology and Industry Scoreboard 2015, 2.6.1, The quantity and quality of scientific production, 2003-12, OECDstat.
- <sup>37</sup> World Bank, Data Bank, Researchers in R&D (per million people), SP.POP.SCIE.RD.P6
- <sup>38</sup> Ibid.
- <sup>39</sup> Chemistry World (2016), “Brazil Science Squeeze”, 3/14/2016, <http://www.rsc.org/chemistryworld/2016/03/brazil-science-research-universities-funding-crisis>
- <sup>40</sup> Ciência sem Fronteiras, “The program, Goals”, (Accessed April 2016), <http://www.cienciasemfronteiras.gov.br/web/csf-eng/goals>
- <sup>41</sup> Ibid.
- <sup>42</sup> National Science Foundation (2016), “Science and Engineering Indicators 2016”, ch. 4, p. 38.
- <sup>43</sup> World Bank, R&D expenditure as % of GDP, Brazil
- <sup>44</sup> OECD (2014), “Main Science and Technology Indicators”, p. 21.
- <sup>45</sup> OECDSTAT, Patents by technology, Triadic Patent families, Inventor(s)'s country(ies) of residence, Priority date, Biotechnology.
- <sup>46</sup> NIH/Clinicaltrials.gov
- <sup>47</sup> Ibid.
- <sup>48</sup> Ibid.
- <sup>49</sup> Folha de S. Paulo (2014), “Group Launches Initiative to Develop Clinical Trials in Brazil” (translated), 4/10/2014, <http://www1.folha.uol.com.br/ciencia/2014/04/1438426-grupo-lanca-iniciativa-para-fomentar-testes-clinicos-no-brasil.shtml>; ABRASCO (2015) “Clinical Trials and ANVISA, an Inverted Prioritization”, 2/24/2015 <https://www.abrasco.org.br/site/2015/02/os-ensaios-clinicos-e-a-anvisa-uma-priorizacao-invertida/>
- <sup>50</sup> A Groh et al (2015), “Venture Capital & Private Equity Country Attractiveness Index 2015”, IESE and EMLYON.
- <sup>51</sup> BRIC Wall (2015), “13th Federal District Court of Rio de Janeiro Holds that ANVISA Can Examine Patentability Requirements of Patent Applications Claiming Pharmaceutical Inventions”, 06/26/2015 <https://bricwallblog.wordpress.com/2015/06/26/13th-federal-district-court-of-rio-de-janeiro-holds-that-anvisa-can-examine-patentability-requirements-of-patent-applications-claiming-pharmaceutical-inventions/>
- <sup>52</sup> Deputies Chamber (2013), “Explanatory Parliamentary Report “Brazil Patent Reform: Innovation Towards Competitiveness”, p.307, [http://infojustice.org/wp-content/uploads/2013/09/Brazilian\\_Patent\\_Reform.pdf](http://infojustice.org/wp-content/uploads/2013/09/Brazilian_Patent_Reform.pdf)
- <sup>53</sup> Rana Gosain, Daniel Advogados/Intellectual Property Magazine (2014), “The Pharma Saga”, 28 April 2014; US Department of State (2015), “Brazil Investment Climate Statement 2015”, p.13, May 2015.
- <sup>54</sup> BRIC Wall Blog (2016), “Expediting Patent Prosecution in Brazil”, 3/29/2016, <https://bricwallblog.wordpress.com/category/brazil/>
- <sup>55</sup> Ibid.
- <sup>56</sup> Lucas & Mercanti (2015).
- <sup>57</sup> World Intellectual Property Review (2014), “Brazil: What To Expect In Intellectual Property 2014”, 1/2/2014.
- <sup>58</sup> Deputies Chamber (2013).
- <sup>59</sup> Licks Attorneys (2015), “Brazilian Patent Statute Under Attack: An Overview Of Potential Changes”, part 3, May 2015.
- <sup>60</sup> BIO (2012), “Proposal for Reform of Brazil’s Bioprospecting and Genetic Resources, Regulations 18 November 2013”, p. 24.
- <sup>61</sup> Ibid.
- <sup>62</sup> Finep, “The Industry”, (Accessed May 2016), [http://www.finep.gov.br/pagina.asp?pag=institucional\\_empresa](http://www.finep.gov.br/pagina.asp?pag=institucional_empresa)
- <sup>63</sup> T Kirchlechner (2013), “Biosimilar Regulatory Overview ANVISA Biosimilars wWrkshop”, Brasilia, 6/25/2013, Sandoz, slide presentation.
- <sup>64</sup> CTNBio, Perguntas mais Frequentes (novo), (Accessed May 2016), <http://www.ctnbio.gov.br/index.php/content/view/18677.html>
- <sup>65</sup> Ibid. See also T. Wilsdon et al (2012), p. 60.
- <sup>66</sup> ABRACRO (2015), “New ANVISA Clinical Research Regulations”, 4/23/2015, <http://www.abracro.org.br/noticias/370-new-anvisa-clinical-research-regulations>
- <sup>67</sup> BRIC Wall blog (2014), “The Brazilian Patent Office Places The Fight Against The Patent Application Backlog As Its Top Priority”, <https://bricwallblog.wordpress.com/2014/11/06/the-brazilian-patent-office-places-the-fight-against-the-patent-application-backlog-as-its-top-priority/>
- and C. Israel (2012), “International Patent Issues: Promoting A Level Playing Field For American Industry Abroad”, Statement before the House Committee On The Judiciary Subcommittee On Intellectual Property, Competition and The Internet, US Congress, 4/26/2012.
- <sup>68</sup> BRIC Wall (2016), “Expediting Patent Prosecution in Brazil, 03/29/2016.
- <sup>69</sup> BRIC Wall (2016), “Brazilian Patent Office and the Patent Prosecution Highway Program”, 02/16/2016.
- <sup>70</sup> OECD (2012), p. 254.

- <sup>71</sup> Agencia Brasil EBC (2016), “Brazil to Become Innovation Exporter”, 1/14/2016. <http://agenciabrasil.ebc.com.br/en/pesquisa-e-inovacao/noticia/2016-01/brazil-become-innovation-exporter>
- <sup>72</sup> Ciencia Estado Blogs (2016), “Legal Framework for Science and Technology: What changes in the lives of investigators?”, 1/13/2016, <http://ciencia.estadao.com.br/blogs/herton-escobar/marco-legal-de-ciencia-e-tecnologia-o-que-muda-na-vida-dos-pesquisadores/>
- <sup>73</sup> US Department of State (2015), “Investment Climate Statement Brazil”, p.6.
- <sup>74</sup> AH Oikawa (2013), “IP Licensing In Brazil: What You Need To Know”, *World Intellectual Property Review*, 6/1/2011; and F. Oliveira do Prado et al. (2010), “Technology Transfer In A Public Brazilian University”, *Triple Helix in the Development of Cities of Knowledge, Expanding Communities and Connecting Regions*, conference proceedings, 10/20/2010.
- <sup>75</sup> Ibid. p. 12.
- <sup>76</sup> WIPO (2015), “Patent Cooperation Treaty Yearly Review”, p.48.
- <sup>77</sup> CNI (2015), “2% Of Entrepreneurs Consider The Degree Of Innovation In Brazil Low Or Very Low, Says The CNI”, 5/12/2015, <http://www.portaldaindustria.com.br/cni/imprensa/2015/05/1,62121/62-dos-empresarios-consideram-o-grau-de-inovacao-no-brasil-baixo-ou-muito-baixo-aponta-pesquisa-da-cni.html>
- <sup>78</sup> Deloitte (2015), “2015 Global Survey of R&D Incentives”, October 2015, p. 8.
- <sup>79</sup> Agencia Brasil EBC (2016).
- <sup>80</sup> See: Resolution CMED nº 4, 6/15/2005, published in the Official Journal on 10/7/2005.
- <sup>81</sup> BMI (2015) “Industry Trend Analysis - New Ban On Medical Lawsuits Would Hamper Drug Access”, October 2015, <http://www.pharmaceuticalsinsight.com/industry-trend-analysis-new-ban-medical-lawsuits-would-hamper-drug-access-oct-2015>.
- <sup>82</sup> Ibid.
- <sup>83</sup> IHS (2016), “Brazilian States Increase ICMS Tax on Medicines”, 2/19/2016, <https://www.ihc.com/country-industry-forecasting.html?ID=10659109997>
- <sup>84</sup> Ibid.
- <sup>85</sup> World Justice Project (2015), “Rule of Law Index 2015”, p. 20.
- <sup>86</sup> World Bank data.
- <sup>87</sup> Ibid.
- <sup>88</sup> IMF (2015), “World Economic Outlook: Adjusting to Lower Commodity Price”, 10/2015, p.2, <http://www.imf.org/external/pubs/ft/weo/2015/02/pdf/text.pdf>
- <sup>89</sup> Klaus Schwab/World Economic Forum (2015).
- <sup>90</sup> Asian Scientist (2016), “China’s Latest 5-year Plan to Focus on Innovation”, 4/6/2016 <http://www.asianscientist.com/2016/04/topnews/china-five-year-plan-innovation-science-spending/>
- <sup>91</sup> Ibid.
- <sup>92</sup> PwC (2016), “Prosperity for the Masses by 2020”, 11/19/2015, <http://www.pwc.de/de/internationale-maerkte/german-business-groups/assets/chinas-13th-five-year-plan-and-its-business-implications.pdf>
- <sup>93</sup> Asia Scientist (2016).
- <sup>94</sup> PwC (2016).
- <sup>95</sup> Asian Scientist (2016).
- <sup>96</sup> Kathleen McLaughlin/Science (2016), “Science Is A Major Plank In China’s New Spending Plan”, 7/3/2016, <http://www.sciencemag.org/news/2016/03/science-major-plank-china-s-new-spending-plan>
- <sup>97</sup> Xinhua (2016), “China Inaugurates National R&D Plan”, 16/2/2016, [http://news.xinhuanet.com/english/2016-02/16/c\\_135104108.htm](http://news.xinhuanet.com/english/2016-02/16/c_135104108.htm)
- <sup>98</sup> L. Qiu et al (2014), “Public Funding And Private Investment For R&D: A Survey In China’s pharmaceutical industry”, *Health Research Policy and Systems*, 12, 27. doi:10.1186/1478-4505-12-27
- <sup>99</sup> Ibid.
- <sup>100</sup> Bird and Bird (2016), “China: CFDA Implements New Review And Approval System For Generic Drugs”, 3/28/2016, <http://www.twobirds.com/en/news/articles/2016/china/cfda-implements-new-review-and-approval-system-for-generic-drugs>
- <sup>101</sup> Ropes&Gray (2015), “China FDA Announces Implementation Scheme To Improve The Drug Approval System”, 11/19/2015, <http://www.mondaq.com/x/444832/Life+Sciences+Biotechnology/China+FDA+Announces+Implementation+Scheme+To+Improve+The+Drug+Approval+System>
- <sup>102</sup> Pugatch Consilium (2016), “Measuring The Global Biomedical Pulse The Biopharmaceutical Investment & Competitiveness (Bci) Survey – 2016”.
- <sup>103</sup> MIT Technology Review (2014), “China’s GMO Stockpiles”, 10/21/2014, (Accessed May 2016), <http://www.technologyreview.com/featuredstory/531721/chinas-gmo-stockpile/>
- <sup>104</sup> Ibid.
- <sup>105</sup> USDA (2015), “China Considering Major Revisions to Biotechnology Regulations”, 21/12/2015, [http://gain.fas.usda.gov/Recent%20GAIN%20Publications/Agricultural%20Biotechnology%20Annual\\_Beijing\\_China%20-%20Peoples%20Republic%20of\\_12-21-2015.pdf](http://gain.fas.usda.gov/Recent%20GAIN%20Publications/Agricultural%20Biotechnology%20Annual_Beijing_China%20-%20Peoples%20Republic%20of_12-21-2015.pdf)

- <sup>106</sup> Ministry of Agriculture of the People's Republic of China, China Vows Zero Tolerance for GM Rice, 30/07/2014, (Accessed May 2016), [http://english.agri.gov.cn/hottopics/bt/201409/t20140919\\_23953.htm](http://english.agri.gov.cn/hottopics/bt/201409/t20140919_23953.htm)
- <sup>107</sup> Greenpeace (2016), "Greenpeace Sampling Finds 93% Of Corn Grown In China's 'Breadbasket' Province Of Illegal GE Strain" 1/6/2016, <http://www.greenpeace.org/eastasia/press/releases/food-agriculture/2015/93-GE-corn-contamination>; CRI English News (2016), "Political Advisers Call for Open-mind on GMO", 3/10/2016, <http://english.cri.cn/12394/2016/03/10/4082s919937.htm>
- <sup>108</sup> Reuters (2016), "China Cracks Down on Illegal GM Crops ahead of Syngenta Deal", 2/5/2016, <http://af.reuters.com/article/commoditiesNews/idAFL3N14803Y?pageNumber=2&virtualBrandChannel=0&sp=tr ue>
- <sup>109</sup> Global Times (2016), "China Rules out Industrial-scale GM Grain Farms", 3/29/2016, <http://www.globaltimes.cn/content/976456.shtml>
- <sup>110</sup> Reuters (2016), "China Seeks Food Security With USD43 Million Bid For Syngenta", 4/2/2016, <http://www.reuters.com/article/us-syngenta-ag-m-a-chemchina-idUSKCN0VB1D9>
- <sup>111</sup> Pamela Smith/Hertz (2016), "China's Next Steps", 4/16/2016, <https://www.hertz.ag/ag-industry/current-headlines/0702bf4c04132016151700/>
- <sup>112</sup> USDA (2015), p. 14.
- <sup>113</sup> USDA (2015), "GAIN Agriculture Biotechnology Annual Report" p.3, 12/21/2015, [http://gain.fas.usda.gov/Recent%20GAIN%20Publications/Agricultural%20Biotechnology%20Annual\\_Beijing\\_China%20-%20Peoples%20Republic%20of\\_12-21-2015.pdf](http://gain.fas.usda.gov/Recent%20GAIN%20Publications/Agricultural%20Biotechnology%20Annual_Beijing_China%20-%20Peoples%20Republic%20of_12-21-2015.pdf)
- <sup>114</sup> R. Campbell (2014), "China and the United States—A Comparison of Green Energy Programs and Policies", *Congressional Research Service*, April 30 2014, p. 8.
- <sup>115</sup> WEF (2016), "Biotechnology Ecosphere in China", February 2016, p.6, [http://www3.weforum.org/docs/IP/2016/CH/WEF\\_CH\\_Biotechnology\\_Ecosphere\\_in\\_China\\_2016.pdf](http://www3.weforum.org/docs/IP/2016/CH/WEF_CH_Biotechnology_Ecosphere_in_China_2016.pdf)
- <sup>116</sup> BP (2015), "BP Statistical Review of World Energy", June 2015, p. 39.
- <sup>117</sup> PwC (2015), p.5.
- <sup>118</sup> Times Higher Education World University Rankings 2015-2016.
- <sup>119</sup> World Bank, Data bank, Scientific and technical journal articles, IP.JRN.ARTC.SC.
- <sup>120</sup> OECD (2015), *Science, Technology and Industry Scoreboard 2015*, 2.6.1 The quantity and quality of scientific production, 2003-12, OECDstat
- <sup>121</sup> Phys.org (2016), "US Science And Technology Leadership Increasingly Challenged By Advances In Asia", 1/19/2016, <http://phys.org/news/2016-01-science-technology-leadership-increasingly-advances.html#jCp>
- <sup>122</sup> National Science Foundation (2016), chapter 2, p. 85.
- <sup>123</sup> Ibid. p.87.
- <sup>124</sup> CNN (2016), "China Gets Into the Genetic Breakthrough Business", 4/28/2016, <http://edition.cnn.com/2016/04/28/health/china-genetic-breakthrough-business/>
- <sup>125</sup> World Bank data bank, Researchers in R&D (per million people), SP.POP.SCIE.RD.P6
- <sup>126</sup> Ibid.
- <sup>127</sup> OECD (2015), "Science and Technology Indicators 2015", p.21.
- <sup>128</sup> Ibid
- <sup>129</sup> OECD (2015), p. 32.
- <sup>130</sup> Pugatch's analysis based on [clinicaltrials.gov](http://clinicaltrials.gov)
- <sup>131</sup> Ibid.
- <sup>132</sup> Ibid.
- <sup>133</sup> OECDSTAT, Patents by technology, Triadic Patent families, Inventor(s)'s country(ies) of residence, Priority date, Biotechnology.
- <sup>134</sup> A Groh et al (2015), "Venture Capital & Private Equity Country Attractiveness Index 2015", IESE and EMLYON.
- <sup>135</sup> M Pugatch & D Torstensson (2010), "Keeping Medicines Safe – A Study of the Regulations Guiding the Approval of Medicines in Emerging Markets", Stockholm Network London.
- <sup>136</sup> RDPAC/BIO (2013), "Building a World-Class Innovative Therapeutic Biologics Industry in China", pp.18-19.
- <sup>137</sup> Ibid.
- <sup>138</sup> Patent Law of the People's Republic of China (1985); Article 26.3 and 4 read: "The description shall set forth the invention or utility model in a manner sufficiently clear and complete so as to enable a person skilled in the relevant field of technology to carry it out; where necessary, drawings are required. The abstract shall state briefly the main technical points of the invention or utility model. The claims shall be supported by the description and shall define the extent of patent protection sought for in a clear and concise manner." In practice, patent examiners interpret this to mean that the applicant should have "completed" the invention at the time of filing. According to SIPO's patent examination guidelines, applications that include a technical solution do not meet sufficiency of disclosure if experimental evidence is not included.
- <sup>139</sup> Liu, J. (2014), "Sufficiency of Patent Disclosure in BRICS", BRICS IP Forum, October 2014.
- <sup>140</sup> Patent Affairs Administration Department, SIPO (2013), "Notice to implement relevant provisions of the Patent Law, Patent Rules and Patent Examination Guidelines in Patent Examination", October 2013.

<sup>141</sup> CCPIT Patent & Trademark Law Office, “SIPO Clarifies the Examination Standard on Sufficient Disclosure of Chemical/Medical Inventions”, February 2014.

<sup>142</sup> Jiaquan IP Law Firm/Lexology, “Drug Patents in China – Clarify Your Drug”, 2/17/2016, <http://www.lexology.com/library/detail.aspx?g=36ca80e9-052a-42e2-851c-b0987e08f9d8>

<sup>143</sup> Note that the challenge to the patent was based on lack of inventive step, although it is not clear whether this was actually the basis for SIPO’s decision; Source: Reuters, “China Rejects Patent Linked To Gilead Hepatitis C Drug”, 6/19/2015, <http://www.reuters.com/article/gilead-sciences-sovaldi-patents-idUSL1N0Z506G20150619>

<sup>144</sup> Regulatory Affairs Professional Society (RAPS), “Sovaldi Patent Rejected in China Following Third-Party Challenge”, 6/19/2015, <http://www.raps.org/Regulatory-Focus/News/2015/06/19/22730/Sovaldi-Patent-Rejected-in-China-Following-Third-Party-Challenge/>

<sup>145</sup> Sanyou/ (2015), “The Latest Patent Application Of Hepatitis C Drug Sovaldi Of Gilead Is Rejected In China”, *Lexology*, 9/11/2015, <http://www.lexology.com/library/detail.aspx?g=6eff80a2-fe80-4698-b4cf-463fcd6e0dcf>

<sup>146</sup> MMLC Group, “China’s Patent Law and the Pharmaceutical Industry”, <https://www.hg.org/article.asp?id=33387>

<sup>147</sup> Thomson Reuters The Patent Lawyer, “The New Patent Dynasty”, pp.34-7, <http://ip.thomsonreuters.com/sites/default/files/new-patent-dynasty.pdf>

<sup>148</sup> Drat Amendment of the Patent Law of the PRC (Draft for Deliberation), <http://images.chinalaw.gov.cn/www/201512/20151202075620423.doc>

<sup>149</sup> USTA (2016), “Special 301 Report”, p.35.

<sup>150</sup> *Ibid.*, p.36.

<sup>151</sup> SFDA Annual Drug Review Report 2014 (translated), <http://www.sfda.gov.cn/WS01/CL0108/125301.html>

<sup>152</sup> International Law Office (2015), “Biosimilars are Regulated Differently in China”, 07/22/2015, <http://www.internationallawoffice.com/Newsletters/Detail.aspx?g=57994138-d11b-49f3-b2d7-0590061421ad&redir=1>

<sup>153</sup> Jones Day (2015), “China Considers Compulsory Licenses to Pharmaceutical Patents”, 11/6/2015, <http://www.mondaq.com/x/441528/Healthcare/China+Considers+Compulsory+Licenses+To+Pharmaceutical+Patents>

<sup>154</sup> USDA (2014), “Agricultural Biotechnology Annual – China”, Report 14032, 12/31/2014, p. 11.

<sup>155</sup> USDA (2015).

<sup>156</sup> M Pugatch & D Torstensson (2010), pp. 22-5.

<sup>157</sup> *Ibid.*

<sup>158</sup> Jones Day (2015), “China Makes Efforts to Reduce Backlog of Drug Approval”, 9/23/2015, <http://www.mondaq.com/x/428922/food+drugs+law/China+Makes+Efforts+To+Reduce+Backlog+Of+Drug+Approvals>

<sup>159</sup> Ropes & Grey (2015), “China FDA Solicits Comments on Resolving the Backlog of Drug Applications”, *China Life Science Alert*, 8/7/2015; Pharmexec (2016), “China’s Changing Clinical Trial Environment”, 3/17/2016, <http://www.pharmexec.com/sponsored-content-china-s-changing-clinical-trial-environment>

<sup>160</sup> Ropes & Gray (2015), “China Announces Final Biosimilars Guideline”, *China Life Science Alert*, 3/6/2015;

DLA Piper LLP (2015), “China’s First Regulatory Framework For Biosimilar Approval”, 5/6/2015, <http://www.lexology.com/library/detail.aspx?g=43e8b20e-967d-4d63-8013-59b3d845afde>

<sup>161</sup> CMS (2015), “A Comparison Of European And Chinese Regulation Of Biosimilar Products”, 10/29/2015, <http://www.cms-lawnow.com/ealerts/2015/10/a-comparison-of-european-and-chinese-regulation-of-biosimilar-products>

<sup>162</sup> USDA (2013), “Agricultural Biotechnology Annual - China”, Report 13033, pp. 6-8.

<sup>163</sup> USDA (2015), “China Amends Seed Law to Develop Seed Industry”, 12/1/2-15; See also the Draft Revised Crop Variety Registration Measure, currently being adopted in line with the Seed Law. Text available at [http://gain.fas.usda.gov/Recent%20GAIN%20Publications/China%20Revised%20Crop%20Variety%20Registration%20Measure\\_Beijing\\_China%20-%20Peoples%20Republic%20of\\_2-24-2016.pdf](http://gain.fas.usda.gov/Recent%20GAIN%20Publications/China%20Revised%20Crop%20Variety%20Registration%20Measure_Beijing_China%20-%20Peoples%20Republic%20of_2-24-2016.pdf)

<sup>164</sup> Reuters (2016), “China Amends Seed Law To Encourage Innovation”, 11/4/2016, <http://www.reuters.com/article/us-china-seeds-idUSKCN0ST1A420151104>

<sup>165</sup> *Ibid.* p. 13.

<sup>166</sup> *Ibid.*

<sup>167</sup> Agri Pulse (2015), “China Commits To 'Further Improve' Biotech Approval Process”, 9/25/2015, <http://www.agri-pulse.com/China-agrees-to-improve-biotech-approvals-09252015.asp>

<sup>168</sup> *Ibid.*

<sup>169</sup> US Chamber of Commerce/American Chamber of Commerce in China (2016), “Joint Comments to the National Development and Reform Commission on the Guideline on Intellectual Property Abuse”, February 2016, <https://chinaipr2.files.wordpress.com/2016/03/ndrc-ip-abuse-guidelines-english.pdf>

<sup>170</sup> GD Graff (2007), “Echoes of Bayh-Dole? A Survey of IP and Technology Transfer Policies in Emerging and Developing Economies”, *Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices*, (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, UK, p. 176.

<sup>171</sup> WIPO (2014), p. 18.

<sup>172</sup> *Ibid.*

- <sup>173</sup> Xinhua (2016), “China Designs Incentives for Scientists to Translate Research into Products”, 2/18/2016, [http://news.xinhuanet.com/english/2016-02/18/c\\_135107419.htm](http://news.xinhuanet.com/english/2016-02/18/c_135107419.htm)
- <sup>174</sup> H. Guo (2007), “IP Management at Chinese Universities”, in A. Krattiger et al, (eds).
- <sup>175</sup> RDPAC and BIO (2013), p. 20.
- <sup>176</sup> Economist Intelligence Unit (2015), “A New Regime for Foreign Investors”, 04/22/2015.
- <sup>177</sup> China IPR, “IP Tax Management in China – Navigating the Thicket in Light of Global Tax Reforms”, 08/14/2015, Deloitte (2015), “SAT Issues Draft Guidance On Transfer Pricing Rules And BEPS Initiatives”, 9/21/2015, <http://www2.deloitte.com/content/dam/Deloitte/global/Documents/Tax/dttl-tax-alert-china-21-september-2015.pdf>
- <sup>178</sup> Deloitte (2015), p. 10.
- <sup>179</sup> Ibid.
- <sup>180</sup> R. Campbell (2014), “China and the United States—A Comparison of Green Energy Programs and Policies”, Congressional Research Service, 4/30/2014, p. 15.
- <sup>181</sup> Ibid.
- <sup>182</sup> WEF (2016), p.7.
- <sup>183</sup> Ibid. pp. 16-8.
- <sup>184</sup> North Head Consulting, “China Healthcare Outlook”, 04/2015, p.4, <http://www.northheadcomms.com/uploads/soft/150506/1-1505061GZ8.pdf>
- <sup>185</sup> North Head Consulting (2015), 07/2015, p.1. Original document available at <http://www.nhpc.gov.cn/yaozs/s3573/201506/36a74780403d4eed96ca93b665620941.shtml>
- <sup>186</sup> State Council document reflecting on the progress of medical reform in 2014, 05/09/2015, followed by two circulars the county-level hospital reform (05/08/2015) and city-level hospital reform (05/17/2015). Information retrieved from North Head Consulting (2015), China Healthcare Outlook, 04/2015, <http://www.northheadcomms.com/uploads/soft/150625/HealthcareNewsletter-June2015Issue.pdf>
- <sup>187</sup> PhRMA (2016), “Special 301 Submission Report”.
- <sup>188</sup> Amendment to the Drug Administration Law. Text available (in Chinese) at <http://www.sda.gov.cn/WS01/CL0784/124980.html>; See also “Standing Committee of the National People’s Congress on Amending the “People’s Republic of China Drug Administration Law” (translated), meeting of 04/24/2015 (in Chinese), [http://www.npc.gov.cn/npc/cwhhy/12jcw/2015-04/25/content\\_1934604.htm](http://www.npc.gov.cn/npc/cwhhy/12jcw/2015-04/25/content_1934604.htm)
- <sup>189</sup> See HIS (2015) “China Confirms Removal of Price Controls on Most Drugs From 1 June”, 05/07/2015, <https://www.ihs.com/country-industry-forecasting.html?ID=1065998991>
- <sup>190</sup> World Justice Project (2015), p. 20.
- <sup>191</sup> World Bank Data.
- <sup>192</sup> Klaus Schwab/World Economic Forum (2015).
- <sup>193</sup> Ibid., p. 142.
- <sup>194</sup> World Bank, World Development Indicators, GDP growth (annual %), Colombia 2000-2014, World Bank database 2016.
- <sup>195</sup> OECD (2015). “OECD Economic Surveys: Colombia”, January 2015, p. 11. [https://www.oecd.org/eco/surveys/Overview\\_Colombia\\_ENG.pdf](https://www.oecd.org/eco/surveys/Overview_Colombia_ENG.pdf)
- <sup>196</sup> OECD (2014), “OECD Reviews of Innovation Policy, Colombia”, p. 15.
- <sup>197</sup> Consejo Nacional de Política Económica y Social República de Colombia Departamento Nacional de Planeación, “Política Para El Desarrollo Comercial De La Biotecnología A Partir Del Uso Sostenible De La Biodiversidad”, P. 7.
- <sup>198</sup> Colciencias (2011), “Presidente Santos Presentó Estrategia Para El Fortalecimiento De Colciencias”, 5/18/2011, <http://www.colciencias.gov.co/noticias/presidente-santos-present-estrategia-para-el-fortalecimiento-de-colciencias>
- <sup>199</sup> Consejo Nacional de Política Económica y Social República de Colombia Departamento Nacional de Planeación, “Política Para El Desarrollo Comercial De La Biotecnología A Partir Del Uso Sostenible De La Biodiversidad”, P. 7.
- <sup>200</sup> El Congreso de la República de Colombia, Ley N° 1450 de 2011 (16 de junio) - Por la cual se expide el Plan Nacional de Desarrollo, 2010-2014, [http://www.wipo.int/wipolex/en/text.jsp?file\\_id=226358](http://www.wipo.int/wipolex/en/text.jsp?file_id=226358).
- <sup>201</sup> National Council for Economic and Social Policy/Department of National Planning (2011), “Policy for the Commercial Development of Biotechnology”.
- <sup>202</sup> Consejo Nacional de Política Económica y Social, República de Colombia, Departamento Nacional de Planeación, Documento CONPES 3697, “Política Para El Desarrollo Comercial De La Biotecnología A Partir Del Uso Sostenible De La Biodiversidad”, <http://www.generacionbio.com/files/CONPES3697.pdf>.
- <sup>203</sup> Ibid.
- <sup>204</sup> Ibid.
- <sup>205</sup> Presidencia Secretaria de Prensa República de Colombia, Informe al Congreso Juan Manuel Santos 2011, pp. 23-25, <http://wsp.presidencia.gov.co/Publicaciones/Documents/InformePresidente2011.pdf>.
- <sup>206</sup> Departamento Nacional de Planeación (2015), “Plan Nacional de Desarrollo 2014-2018 Todos por un Nuevo País”, p. 23.
- <sup>207</sup> Ley 1753 de 2015, Departamento Nacional de Planeación (2015), “Plan Nacional de Desarrollo 2014-2018 Todos por un Nuevo País”, p. 1,119.
- <sup>208</sup> Chandrasekhar, A. “Colombian Minister Proposes Ending Novartis Patent”, Swiss Info, 4/28/2016

- <sup>209</sup> Ley 1753 de 2015, Departamento Nacional de Planeación (2015), pp. 1,119-1,121.
- <sup>210</sup> Ministerio de Ambiente y Desarrollo Sostenible, (2014). El Programa Nacional de Biocomercio Sostenible de Colombia 2014 – 2024 (PNBS).
- <sup>211</sup> Ibid., p. 19.
- <sup>212</sup> Ibid., p. 114.
- <sup>213</sup> Ibid., pp. 89-93.
- <sup>214</sup> El Tiempo (2014), “Biodiversidad, La Apuesta Científica De Colombia Colciencias Busca Poner Al País Entre Los Tres Más Innovadores De América Latina”, 12/12/2014, interview with the Director of Colciencias: <http://www.eltiempo.com/estilo-de-vida/ciencia/colciencias-entrevista-con-la-directora-yaneth-giha/14963565>
- <sup>215</sup> Ibid.
- <sup>216</sup> BMI Research, “Colombia Pharmaceuticals and Healthcare Report Q2 2016”, 2016.
- <sup>217</sup> Fedesarrollo/ANDI Cámara de la Industria Farmacéutica, “Informe del Sector Farmacéutico”, July 2015
- <sup>218</sup> El País, “Tecnológicas Entra Al Negocio De Los Medicamentos Biosimilares”, 4/14/2016
- <sup>219</sup> G. Buitrago Hurtado (2012), “Tres décadas de biotecnología en Colombia”; Revista Colombiana de Biotecnología 2012, XIV(2).
- <sup>220</sup> Iain M. Cockburn, Jean O. Lanjouw, Mark Schankerman (2014) “Patents and the Global Diffusion of New Drugs”, NBER Working Paper No. 20492, Table A2, p. 43.
- <sup>221</sup> Pugatch Consilium (2016), “Measuring The Global Biomedical Pulse The Biopharmaceutical Investment & Competitiveness (Bci) Survey – 2016”.
- <sup>222</sup> G. Buitrago Hurtado (2012).
- <sup>223</sup> Universidad de los Andes Centro de estudios ganaderos y agrícolas (CEGA) y Agro-Bio (2011), “El Beneficio Económico Por La Adopción De La Tecnología De OGM Para Maíz En Colombia”.
- <sup>224</sup> See, for instance, Asociación de Biotecnología Vegetal Agrícola (Agro-Bio), “Transgénicos en el mundo, Colombia y Región Andina”, <http://agrobio.org/agrobio/transgenicos-en-el-mundo-colombia-region-andina/>
- <sup>225</sup> Agronegocios (2016), “El Papel De La Biotecnología En El Plan Colombia Siembra”, 3/3/2016.
- <sup>226</sup> E Trigo et al (2010), “Biotecnología Agropecuaria para el Desarrollo en América Latina: Oportunidades y Retos”, Inter-American Development Bank and FAO, Working Document LAC/01/10, p. 8.
- <sup>227</sup> Semana (2016), “La Inestable Apuesta Por Los Biocombustibles”, 2/20/2016, <http://www.semana.com/economia/articulo/biocombustibles-ya-no-son-tan-buen-negocio/461232>; El Espectador, “En Colombia se producen biocombustibles sostenibles”, 5/20/2012, <http://www.elespectador.com/noticias/economia/colombia-se-producen-biocombustibles-sostenibles-articulo-344776>
- <sup>228</sup> ProColombia, “Inversión en el Sector de Biocombustibles en Colombia”, <http://inviertaencolombia.com.co/sectores/agroindustria/biocombustibles.html>
- <sup>229</sup> Semana (2016).
- <sup>230</sup> Ibid.
- <sup>231</sup> La Prensa (2016), “Los Biocombustibles Abren Un Nuevo Mercado”, 4/23/2016, <http://www.laprensa.hn/economia/953039-410/los-biocombustibles-abren-un-nuevo-mercado>
- <sup>232</sup> G. Buitrago Hurtado (2012).
- <sup>233</sup> BP, “Statistical Review of World Energy”, 2015.
- <sup>234</sup> Times Higher Education World University Rankings 2015-2016 .
- <sup>235</sup> World Bank Data, Scientific and technical journal articles, IP.JRN.ARTC.SC.
- <sup>236</sup> World Bank Data, Researchers in R&D (per million people), SP.POP.SCIE.RD.P6
- <sup>237</sup> World Bank, R&D expenditure as % of GDP, Brazil.
- <sup>238</sup> OECD (2014), “Main Science and Technology Indicators”, p. 21.
- <sup>239</sup> OECDSTAT, Patents by technology, Triadic Patent families, Inventor(s)'s country(ies) of residence, Priority date, Biotechnology.
- <sup>240</sup> Ibid.
- <sup>241</sup> Ibid.
- <sup>242</sup> A Groh et al (2015), “Venture Capital & Private Equity Country Attractiveness Index 2015”, IESE and EMLYON.
- <sup>243</sup> US Chamber of Commerce (2016) “Infinite Possibilities: 2016 International IP Index”, pp. 107-9, unabridged report. See also L Helfer and K Alter, “The Influence of the Andean Intellectual Property Regime on Access to Medicines in Latin America” in eds R Dreyfuss and C Rodriguez-Garavito, eds, (2014) *Balancing Wealth and Health*, OUP.
- <sup>244</sup> Ley 1753 de 2015, Departamento Nacional de Planeación (2015), “Plan Nacional de Desarrollo 2014-2018 Todos por un Nuevo País,” p. 1,119.
- <sup>245</sup> MinSalud (2016), “Informe Sobre La Recomendación Al Ministro De Salud Y Protección Social En Relación Con La Solicitud De Declaratoria De Interés Público Del Imatinib Con Fines De Licencia Obligatoria”, 2/24/2016; “Stat News, “Colombian Government Recommendation Puts Novartis Cancer Drug At Jeopardy”, 3/7/2016
- <sup>246</sup> K Vyas/ (2016), “Colombia Threatens to Override Novartis’s Patent on Gleevec”, *Wall Street Journal*, 5/20/2016.
- <sup>247</sup> J Symmes Cobb & LJ Acosta (2016), “Colombia To Set New Price For Novartis Cancer Drug: Minister”, *Reuters*, 6/9/2016.

- <sup>248</sup> V. Gomez (2014), “Hands-On The Regulations In Colombia: Main Regulations & Features, Drug Information Association”, pp. 10-11, [http://www.sbfm.org.br/pdf-eventos-2/10th-laccr/20Out13/TUTORIAL2\\_Vivian\\_Gomez\\_20Out13.pdf](http://www.sbfm.org.br/pdf-eventos-2/10th-laccr/20Out13/TUTORIAL2_Vivian_Gomez_20Out13.pdf).
- <sup>249</sup> Ibid., pp. 15-24.
- <sup>250</sup> ProColombia, “16 Colombian Clinics Among The Best 40 In Latin America”, <http://www.procolombia.co/en/health-colombia/health-turism-news/16-colombian-clinics-among-best-40-latin-america>.
- <sup>251</sup> Interventional Concepts, Inc., “Why Colombia”, <http://interventionalconcepts.net/colombia/>.
- <sup>252</sup> Ibid.; Colombia Co (2014), “Colombia Promotes itself as a Destination for Clinical Research”, 8/12/2014, <http://www.colombia.co/en/exports/colombia-promotes-destination-clinical-research.html>.
- <sup>253</sup> AFIDRO (2016), “Investigación Clínica Informe Técnico”, pp. 3-6.
- <sup>254</sup> Colombia Co (2014).
- <sup>255</sup> D. P. Alvarez (2012), “El Entorno De La Investigación Clínica En Colombia: Gestión En Los Centros De Investigación A La Luz Del Proceso De Certificación En Buenas Prácticas Clínicas, Maestría En Administración”, Universidad Nacional De Colombia, Bogotá, October 2012, pp. 50-54, <http://www.bdigital.unal.edu.co/8807/1/940742.2012.pdf>.
- <sup>256</sup> Registros Médicos Electrónicos en América Latina y el Caribe, Análisis de la Discusión en los Foros RELACIS sobre la situación actual y recomendaciones para la región, p. 20, [www.relacis.org/index.php/biblioteca-usuarios/materiales-grupos/biblioteca/materiales-grupos/gt10-registros-medicos-electronicos/registros-medicos-electronicos-en-america-latina-y-el-caribe](http://www.relacis.org/index.php/biblioteca-usuarios/materiales-grupos/biblioteca/materiales-grupos/gt10-registros-medicos-electronicos/registros-medicos-electronicos-en-america-latina-y-el-caribe).
- <sup>257</sup> INVIMA (2016), “Invima Reduce El Tiempo De Evaluación De Protocolos De Investigación A Dos Meses”, 12.4.2016, <https://www.invima.gov.co/invima-reduce-el-tiempo-de-evaluaci%C3%B3n-de-protocolos-de-investigaci%C3%B3n-a-dos-meses>.
- <sup>258</sup> Ibid.
- <sup>259</sup> USDA (2015), “Colombia, Agricultural Biotechnology Annual”, 10/26/2015.
- <sup>260</sup> OECD (2014), “OECD Reviews of Innovation Policy COLOMBIA 2014”, pp. 237-9.
- <sup>261</sup> INNPULSA (2013), Part B (*ENTREGABLE B*), slide 461. (Unofficial translation: “Rules of industrial property in Colombia are very restrictive, preventing, for example, second use patents, placing the country, its productivity and its researchers in a clear inferiority to other leading countries in biotechnology. In addition, the regulations which ensure industrial property rights for companies which collaborate with universities and public research centers are not clear. With regards to technology transfer: it is necessary to incentivize the transfer of research and value creation which facilitate the participation of start-up companies in public research and royalties from realized patents”).
- <sup>262</sup> E&Y (2013), “Worldwide R&D Incentives Reference Guide 2013–2014”, pp. 49-52.
- <sup>263</sup> Ley Estatutaria 1751, Por Medio De La Cual Se Regula El Derecho Fundamental A La Salud Y Se Dictan Otras Disposiciones, article 23, 2/16/2015, PhRMA (2016), “Special 301 Submission”, p. 99.
- <sup>264</sup> Ibid.
- <sup>265</sup> A Kershaw (2015) “Sustainability Of Colombian Healthcare Reform”, *IHS Life Sciences Blog*, 4/13/2015.
- <sup>266</sup> World Justice Project (2015), “Rule of Law Index 2015”, p. 20.
- <sup>267</sup> The World Bank (2015), India data, <http://data.worldbank.org/country/india>
- <sup>268</sup> Klaus Schwab /World Economic Forum (2015).
- <sup>269</sup> Press Information Bureau Government of India Ministry of Science & Technology (2015), “National Biotechnology Development Strategy 2015-2020”, 12/31/2015, <http://pib.nic.in/newsite/PrintRelease.aspx?relid=134035>
- <sup>270</sup> Indiatoday.in (2015), “India Launches New Biotech Strategy Under Make in India Program: All you Must Know”, 12/31/2015, <http://indiatoday.intoday.in/education/story/national-biotechnology-strategy/1/559411.html>
- <sup>271</sup> Huffington Post (2016), “How Bharat Biotech Made Its Breakthrough In Developing A Vaccine For Zika Virus”, 2/7/2016, [http://www.huffingtonpost.in/2016/02/07/zika-virus\\_0\\_n\\_9179776.html](http://www.huffingtonpost.in/2016/02/07/zika-virus_0_n_9179776.html)
- <sup>272</sup> Press Information Bureau Government of India, Ministry of Science & Technology (2015).
- <sup>273</sup> Government of India (2016), “Start-up India Action Plan”, (accessed May 2016), <http://startupindia.gov.in/actionplan.php>
- <sup>274</sup> Business Standard (2016), “Biotechnology Start-ups Get a Boost with Tax Waiver on Services from Incubators”, 1/3/2016, [http://www.business-standard.com/budget/article/biotechnology-start-ups-get-a-boost-with-tax-waiver-on-service-from-incubators-116030101019\\_1.html](http://www.business-standard.com/budget/article/biotechnology-start-ups-get-a-boost-with-tax-waiver-on-service-from-incubators-116030101019_1.html)
- <sup>275</sup> Chandrashekar Gampawar (2015), “Sector: Biotechnology – Make in India”, 1/8/2015, <https://www.linkedin.com/pulse/sector-biotechnology-make-india-chandrashekar-gampawar>
- <sup>276</sup> Justin Chakma/New England Journal of Medicines (2014), “Asia's Ascent — Global Trends in Biomedical R&D Expenditures”, *N Engl J Med* 2014; 370:3-6, 1/2/2014.
- <sup>277</sup> Organization of Pharma Producers of India (2015), “Annual Report 2014-2015”, 10/17/2015, <https://www.indiaoppi.com/sites/default/files/PDF%20files/Annual%20Report%202014-15.pdf>
- <sup>278</sup> The India Times (2015), “India, US Ink Mous On Health Infrastructure, Cancer Research, Technology”, [http://articles.economicstimes.indiatimes.com/2015-06-25/news/63831429\\_1\\_cancer-research-injury-prevention-icmr](http://articles.economicstimes.indiatimes.com/2015-06-25/news/63831429_1_cancer-research-injury-prevention-icmr)



- <sup>279</sup> Department of Biotechnology – Ministry of Science & Technology, Medical Biotechnology, (Accessed May 2016), <http://www.dbtindia.nic.in/programmes/program-medical-biotechnology>
- <sup>280</sup> Ibid.
- <sup>281</sup> Ibid. See ‘Major Achievements’, <http://www.dbtindia.nic.in/programmes/program-medical-biotechnology/chronic-disease-biology/major-achievements>
- <sup>282</sup> Ibid.
- <sup>283</sup> Ibid.
- <sup>284</sup> PhRMA (2016), “Special 301 Submission Report”, p.44; The Indu (2016), “Pharma and Biotech Sector Must Get their Due in Budget”, 2/5/2016, “<http://www.thehindu.com/business/pharma-and-biotech-sector-must-get-its-due-in-budget/article8194415.ece>”
- <sup>285</sup> World Bank data bank, Health expenditure, total (% of GDP).
- <sup>286</sup> Ibid. Health expenditure, public (% of total health expenditure).
- <sup>287</sup> OECDSTAT, OECD Health Statistics 2015 - Frequently Requested Data.
- <sup>288</sup> Iain M. Cockburn, Jean O. Lanjouw, Mark Schankerman (2014) “Patents and the Global Diffusion of New Drugs”, NBER Working Paper No. 20492, Table A2, p. 43.
- <sup>289</sup> Pugatch Consilium (2016), “Measuring The Global Biomedical Pulse The Biopharmaceutical Investment & Competitiveness (Bci) Survey – 2016”.
- <sup>290</sup> ISAAA (2016), “Executive Summary: Global Status of Commercialized Biotech/GM Crops: 2014 - ISAAA Brief 51-2015”, 4/21/2016.
- <sup>291</sup> Ibid.
- <sup>292</sup> USDA (2015), “Agricultural Biotechnology Annual”, 7/10/2015, p.4, [http://gain.fas.usda.gov/Recent%20GAIN%20Publications/Agricultural%20Biotechnology%20Annual\\_New%20elhi\\_India\\_7-10-2015.pdf](http://gain.fas.usda.gov/Recent%20GAIN%20Publications/Agricultural%20Biotechnology%20Annual_New%20elhi_India_7-10-2015.pdf)
- <sup>293</sup> Department of Science and Technology, Press Releases, ‘New Millennium Indian Technology Leadership Initiative (NMITLI) Scheme’, 2/27/2009, (Accessed May 2016), [http://dst.gov.in/whats\\_new/press-release09/new-millennium-scheme.htm](http://dst.gov.in/whats_new/press-release09/new-millennium-scheme.htm)
- <sup>294</sup> Council of Scientific and Industrial Research, Press Releases, “New Millennium Indian Technology Leadership Initiative Scheme Expanded”, 2/23/2009, (Accessed May 2016), <http://www.csir.res.in/external/Heads/collaborations/nmitli.pdf>
- <sup>295</sup> Ibid
- <sup>296</sup> Ibid.
- <sup>297</sup> Department of Biotechnology – Ministry of Science & Technology, Agriculture Biotechnology
- <sup>298</sup> Ibid
- <sup>299</sup> Ibid.
- <sup>300</sup> Ibid.
- <sup>301</sup> Ibid.
- <sup>302</sup> National Bioresource Development Board – Overview Document, (Accessed May 2016), <http://www.dbtindia.nic.in/wp-content/uploads/NBDB-inputs.pdf>
- <sup>303</sup> Ibid.
- <sup>304</sup> Ibid.
- <sup>305</sup> Ministry of New and Renewable Energy (2009), “National Policy on Biofuels”, p.4, [http://mnre.gov.in/file-manager/UserFiles/biofuel\\_policy.pdf](http://mnre.gov.in/file-manager/UserFiles/biofuel_policy.pdf)
- <sup>306</sup> Ibid., p.6.
- <sup>307</sup> Department of Biotechnology – Ministry of Science & Technology.
- <sup>308</sup> Business Standard (2016), “Ethanol Blending Still Partly Stuck”, 8/28/2015, [http://www.business-standard.com/article/markets/ethanol-blending-still-partly-stuck-115082900005\\_1.html](http://www.business-standard.com/article/markets/ethanol-blending-still-partly-stuck-115082900005_1.html)
- <sup>309</sup> BioEnergyConsult (2015), “Biodiesel Program in India, an Analysis”, 8/18/2015, <http://www.bioenergyconsult.com/tag/national-policy-on-biofuels/>
- <sup>310</sup> Biofuels-news (2015), “New Biodiesel Association Will Expand Biodiesel Market In India “, 5/1/2015, [http://biofuels-news.com/display\\_news/9184/new\\_biodiesel\\_association\\_will\\_expand\\_biodiesel\\_market\\_in\\_india/](http://biofuels-news.com/display_news/9184/new_biodiesel_association_will_expand_biodiesel_market_in_india/)
- <sup>311</sup> The Indu (2015), “Centre Seeks public Feedback on National Biofuels policy”, 8/19/2015, <http://www.thehindubusinessline.com/economy/policy/centre-seeks-public-feedback-on-national-biofuels-policy/article7558060.ece>; The India Times (2015), “Government Seeks Comments On Reframing National Biofuel Policy”, 8/19/2015, [http://articles.economictimes.indiatimes.com/2015-08-19/news/65592230\\_1\\_national-policy-biofuels-oil-marketing-companies](http://articles.economictimes.indiatimes.com/2015-08-19/news/65592230_1_national-policy-biofuels-oil-marketing-companies)
- <sup>312</sup> BP (2015), “Statistical Review of World Energy 2015”, p. 39.
- <sup>313</sup> Ibid.
- <sup>314</sup> Times Higher Education World University Rankings 2015-2016.
- <sup>315</sup> World Bank, Data bank, Scientific and technical journal articles, IP.JRN.ARTC.SC.
- <sup>316</sup> OECD (2015), “Science, Technology and Industry Scoreboard 2015”, 2.6.1, The quantity and quality of scientific production, 2003-12, OECDstat.
- <sup>317</sup> OECD (2014), p. 26.
- <sup>318</sup> World Bank data bank, Researchers in R&D (per million people), SP.POP.SCIE.RD.P6
- <sup>319</sup> World Bank Research and development expenditure (% of GDP).

- <sup>320</sup> OECD (2012), p. 312.
- <sup>321</sup> Pugatch's Analysis based on [clinicaltrials.gov](http://clinicaltrials.gov)
- <sup>322</sup> Ibid.
- <sup>323</sup> Ibid.
- <sup>324</sup> OECDSTAT, Patents by technology, Triadic Patent families, Inventor(s)'s country(ies) of residence, Priority date, Biotechnology.
- <sup>325</sup> A Groh et al (2015), "Venture Capital & Private Equity Country Attractiveness Index 2015", IESE and EMLYON.
- <sup>326</sup> Text available at [http://dipp.gov.in/English/Schemes/Intellectual\\_Property\\_Rights/National\\_IPR\\_Policy\\_12.05.2016.pdf](http://dipp.gov.in/English/Schemes/Intellectual_Property_Rights/National_IPR_Policy_12.05.2016.pdf)
- <sup>327</sup> Reuters (2016), "India Announces New Trademark, Patent Policy Amid Global Pressure", 5/14/2016, <http://in.reuters.com/article/india-patents-policy-idINKCN0Y50PY>
- <sup>328</sup> Financial Express (2016), "OPPI Facilitates A Panel Discussion On National IP Policy", 6/9/2016, <http://www.financialexpress.com/article/pharma/latest-updates/oppi-facilitates-a-panel-discussion-on-national-ipr-policy/279024/>
- <sup>329</sup> The Economic Times (2016), "India's New IPR Policy Will Foster Innovation: US official", 5/18/2016, [http://articles.economictimes.indiatimes.com/2016-05-18/news/73177027\\_1\\_ipr-policy-national-intellectual-property-rights-arun-m-kumar](http://articles.economictimes.indiatimes.com/2016-05-18/news/73177027_1_ipr-policy-national-intellectual-property-rights-arun-m-kumar)
- <sup>330</sup> Economic and Political Weekly (2016), "Why New IPR Policy Is Inadequate", <http://www.epw.in/journal/2016/21/commentary/why-new-ipr-policy-inadequate.html#sthash.uYyqbksi.dpuf>
- <sup>331</sup> LiveMint (2016), "New Intellectual Property Rights Policy A Mix Baggage For Indian Pharma", 5/16/2016, <http://www.livemint.com/Politics/fiYpOZYx3OB97pIatCOhBK/New-intellectual-property-rights-policy-a-mix-baggage-for-In.html>
- <sup>332</sup> Financial Express (2016), "OPPI Facilitates A Panel Discussion On National IP Policy", 6/9/2016, <http://www.financialexpress.com/article/pharma/latest-updates/oppi-facilitates-a-panel-discussion-on-national-ipr-policy/279024/>
- <sup>333</sup> BIO (2012), The Comments of the Biotechnology Industry Organization on India's Draft National IPR Strategy as Prepared by the Sectoral Innovation Council in IPR".
- <sup>334</sup> See: D Torstensson & M Pugatch (2010), pp. 26-32.
- <sup>335</sup> T Clarke & B Berkrot (2014). "Unease Grows among U.S. Doctors Over Indian Drug Quality", *Reuters*, 3/18/2014; K Thomas (2013). "U.S. Bans Import of Generic Drugs from Indian Plant", *The New York Times*, 9/17/2013. For details of the investigation of Ranbaxy see: CBS News (2013), "Ranbaxy whistleblower reveals how he exposed massive biopharmaceutical fraud", 11/6/2013.
- <sup>336</sup> Raps (2016), "India Releases New Biosimilars Guidance", 3/28/2016, <http://www.raps.org/Regulatory-Focus/News/2016/03/28/24638/India-Releases-New-Biosimilars-Guidance/>
- <sup>337</sup> CDSCO (2016), "Guidelines on Similar Biologic: Regulatory Requirements for Marketing Authorization in India", draft guidelines published March 2016.
- <sup>338</sup> WIPO (2014), pp. 18-9.
- <sup>339</sup> WIPO (2015), p. 46.
- <sup>340</sup> WIPO (2015), p. 45.
- <sup>341</sup> EU Commission, ERAWATCH, Platform on Research and Innovation policies and systems, India, Knowledge Transfer.
- <sup>342</sup> EY (2015), "Doing Business in India 2015-16", p. 185.
- <sup>343</sup> LiveMint (2016).
- <sup>344</sup> EY (2016), "Global Tax Alert: India's Budget 2016 Includes Significant International Tax Proposals", 3/4/2016.
- <sup>345</sup> Business Standard (2016).
- <sup>346</sup> The Times of India (2016), "Budget 2016: Technology-Related Announcements", 2/29/2016, <http://timesofindia.indiatimes.com/tech/tech-news/budget-2016-technology-related-announcements/articleshow/51190098.cms>
- <sup>347</sup> USTR (2016), 2016 Special 301 Report", p.45.
- <sup>348</sup> Ibid, p. 51; Economist Intelligence Unit (2014), "Pricing Pressure Mount", 07/28/2014; BMI Research, "India Pharmaceutical and Healthcare Report 2015".
- <sup>349</sup> Times of India (2015a), "Government May Negotiate Price of Drugs Before Market Entry", 01/23/2015, <http://timesofindia.indiatimes.com/india/Govt-may-negotiate-price-of-drugs-before-market-entry/articleshow/45986019.cms>; OPPI (2015), "Government Price Controls for Patented Medicines in India", 05/2015, <https://www.indiaoppi.com/sites/default/files/PDF%20files/Position%20on%20Price%20Control%20on%20Patented%20Medicine%20-%20May,%202015.pdf>
- <sup>350</sup> World Justice Project (2015), p. 20.
- <sup>351</sup> World Bank (2015).
- <sup>352</sup> World Bank Data.
- <sup>353</sup> World Economic Forum (2015).
- <sup>354</sup> US Department of State (2015), "Investment Climate Statement-Israel".
- <sup>355</sup> Ibid.

- <sup>356</sup> Invest in Israel website (accessed May 2016), “Technological Incubators”, <http://www.investinIsrael.gov.il/NR/exeres/5E9C9131-8110-4FE8-BE6C-EE2530D055B1.htm>
- <sup>357</sup> Ministry of Economy, “Annual Innovation Report 2015”, [http://madan\\_mag.calltext.co.il/?article=1](http://madan_mag.calltext.co.il/?article=1); Calcalist (2015), “New Program: The Chief Scientist will Seek Visas for Foreign High-tech Entrepreneurs”, 04/13/2015, (translated), <http://www.calcalist.co.il/internet/articles/0,7340,L-3656732,00.html>
- <sup>358</sup> Government Decision No. 2032 of 09/28/2015, <http://www.pmo.gov.il/Secretary/GovDecisions/2014/Pages/des2032.aspx>
- <sup>359</sup> Herzog Fox and Neeman (2016), “New Era for the OCS – Establishment of a National Authority for Technological Innovation”, 1/7/2016.
- <sup>360</sup> The Scientist Magazine, “Innovation Nation”, 7/1/2013.
- <sup>361</sup> Ministry of Industry and Trade (2010), “Israel Bio-Plan 2000-2010: Realizing Biotechnology Potential in Israel”.
- <sup>362</sup> Made in Israel, “A Comprehensive Guide to Israel’s Biotech Industry”, <http://www.madein-israel.com/selectedArticle.aspx?articleId=11>
- <sup>363</sup> Walker, A. (2012), “Biotech in Israel – a Land of Promise”, Alacrita Consulting, May 2012, <http://www.alacritaconsulting.com/whitepapers/biotech-in-israel-a-land-of-promise/>
- <sup>364</sup> Ministry of Economy (2015).
- <sup>365</sup> PR NewsWire (2014), “Israel Pharma Market Worth USD2.3billion by 2020”, 10/7/2014, <http://www.prnewswire.com/news-releases/israel-pharmaceuticals-market-worth-23b-by-2020-says-a-healthcare-regulatory-and-reimbursement-landscape-report-278393081.html>
- <sup>366</sup> State of Israel and Ministry of Economy (2014), “Israel Biopharma Industry Report”, p.59, <http://www.investinIsrael.gov.il/NR/rdonlyres/5A777305-A5DB-420E-8054-E1D15D1A921F/0/IsraelBioPharmaIndustryReport.pdf>
- <sup>367</sup> Ibid; NoCamels Israeli Innovation News (2014), “From Startup Nation To Scale-Up Nation”, 12/31/2014, Israel Reached New Heights In 2014 <http://nocamels.com/2014/12/israel-tech-startup-nation-2014/>
- <sup>368</sup> Yeda, “Technology transfer”, Protalix Biotherapeutics, “Elelyso”, <http://www.protalix.com/products/elelyso-taliglucerase-alfa.asp>
- <sup>369</sup> Iain M. Cockburn, Jean O. Lanjouw, Mark Schankerman (2014) “Patents and the Global Diffusion of New Drugs”, NBER Working Paper No. 20492, Table A2, p. 43.
- <sup>370</sup> Pugatch Consilium (2016) “Measuring The Global Biomedical Pulse The Biopharmaceutical Investment & Competitiveness (Bci) Survey – 2016”.
- <sup>371</sup> USDA (2015), “GAIN Report, Israel”, 7/15/2015, p.1.
- <sup>372</sup> The Law Library of Congress, “Restrictions on Genetically Modified Organisms: Israel”, [https://www.loc.gov/law/help/restrictions-on-gmos/israel.php#\\_ftnref1](https://www.loc.gov/law/help/restrictions-on-gmos/israel.php#_ftnref1)
- <sup>373</sup> USDA (2015).
- <sup>374</sup> Ibid.
- <sup>375</sup> Ibid.
- <sup>376</sup> Biofortified (2015), “A Look at GMO Policies in Different Nations”, 7/6/2015, <https://www.biofortified.org/2015/07/a-look-at-gmo-policies-in-different-nations/>
- <sup>377</sup> USDA (2015).
- <sup>378</sup> Prime Minister Office, (2011) “Government Resolution N.5327: Reducing Israeli Dependence on Petroleum-Based Fuels in Transportation”, <http://www.pmo.gov.il/English/PrimeMinistersOffice/DivisionsAndAuthorities/OilFree/Documents/GovernmentResolution5327.pdf>
- <sup>379</sup> Jerusalem Post (2015), “Burgeoning Alternative Fuel Firms In Israel Grow Fivefold In Less Than Three Years”, 9/30/2015, <http://www.jpost.com/Business-and-Innovation/Environment/Burgeoning-alternative-fuel-firms-in-Israel-grow-fivefold-in-less-than-three-years-419446>
- <sup>380</sup> Prime Minister Office, (2011) Resolution 2790: Executing the National Plan to Develop Technologies That Reduce the Global Use of Petroleum-Based Fuels in Transportation and to Boost Knowledge-Based Industries Focusing on this Field”, 1/30/2011.
- <sup>381</sup> The Jerusalem Post (2014), “Seeking To Reduce Oil Dependence, Netanyahu Awards Cash Prize To Solar-Power Innovators”, 10/6/2014, <http://www.jpost.com/Israel-News/As-part-of-program-to-reduce-oil-dependence-Netanyahu-awards-cash-prize-to-solar-power-innovators-378149>
- <sup>382</sup> Fuel Choice Initiative, Presentation, [http://www.fuelchoicesinitiative.com/files/pics/Fuel\\_choices\\_Initiative.pdf](http://www.fuelchoicesinitiative.com/files/pics/Fuel_choices_Initiative.pdf)
- <sup>383</sup> Prime Minister Office, Alternative Fuels Administration, <http://www.pmo.gov.il/English/PrimeMinistersOffice/DivisionsAndAuthorities/OilFree/Pages/OilTech.aspx>; Watec Israel 2015, “Israeli Innovation In Solar Energy, Bioconversion And Much More Is Developing Renewable Resources To Replace Traditional Fossil Fuels” (Accessed June 2016), <http://watec-israel.com/catalogue/article-7.html>
- <sup>384</sup> The Jerusalem Post (2015).
- <sup>385</sup> Watec Israel 2015; Friends of Volcani, “Environmental Sustainability, Biodiesel Breakthroughs”, <http://www.friendsofvolcani.org/#!/environmental-sustainability/vhsz9>

- <sup>386</sup> Jerusalem Post (2015), “Initial Approval Granted to Renewable Energy Bill”, 12/21/2015, <http://www.jpost.com/Business-and-Innovation/Environment/Initial-approval-granted-to-renewable-energy-bill-437916>
- <sup>387</sup> Ibid.
- <sup>388</sup> Ibid.
- <sup>389</sup> The Jerusalem Post (2015), “OECD: Israelis Among Highest Educated In The Developed World”, 11/25/2015, <http://www.jpost.com/Israel-News/OECD-Israelis-among-highest-educated-in-the-developed-world-435264>
- <sup>390</sup> Times Higher Education World University Rankings 2015-2016.
- <sup>391</sup> World Bank, Data bank, Scientific and technical journal articles, IP.JRN.ARTC.SC.
- <sup>392</sup> OECD (2015), “Science, Technology and Industry Scoreboard 2015”, 2.6.1 The quantity and quality of scientific production, 2003-12, OECDstat.
- <sup>393</sup> OECD (2016), p.29.
- <sup>394</sup> Ibid., p.21.
- <sup>395</sup> OECD, Key Biotechnology Indicators, <http://oe.cd/kbi>;
- <sup>396</sup> OECD (2016), p.32.
- <sup>397</sup> OECD.Stat, Biotech R&D as a percentage of BERD (Business enterprise R&D).
- <sup>398</sup> NIH/Clinicaltrials.gov
- <sup>399</sup> Ibid.
- <sup>400</sup> Ibid.
- <sup>401</sup> OECDSTAT, Patents by technology, Triadic Patent families, Inventor(s)'s country(ies) of residence, Priority date, Biotechnology.
- <sup>402</sup> Made in Israel, “A Comprehensive Guide to Israel’s Biotech Industry”, <http://www.madein-israel.com/selectedArticle.aspx?articleId=11>; Financial Times (2016), “Israeli investors’ enthusiasm for start-ups bucks global trend” 3/22/2016, <http://www.ft.com/intl/cms/s/0/f58402d2-c900-11e5-a8ef-ea66e967dd44.html#axzz4Ak6s0VUt>
- <sup>403</sup> Fierce Biotech, “Israeli Biotech Royalty In Talks With Biogen About \$100M VC Fund”, 11/19/2015
- <sup>404</sup> RAD BioMed, “Overview”, <http://www.radbiomed.com/About/Who-We-Are>
- <sup>405</sup> Times of Israel (2015), “J&J, Takeda Team Up To Open Israeli Biotech Incubator”, 1/19/2015, <http://www.timesofisrael.com/jj-takeda-team-up-to-open-israeli-biotech-incubator/>
- <sup>406</sup> A Groh et al (2015), “Venture Capital & Private Equity Country Attractiveness Index 2015”, IESE and EMLYON.
- <sup>407</sup> Pharmacist Ordinance, 1981.
- <sup>408</sup> RC Attorneys (2012), “Israeli Patent Act Amendment - Early Publication of Patent Applications and Other Changes”, 10/01/2012, <http://www.rcip.co.il/article/early-publication-and-other-significant-revisions-introduced-in-an-amendment-of-the-israeli-patents-law/>
- <sup>409</sup> Ministry of Health website (accessed May 2016), “Quality Management System Certification”, <http://www.health.gov.il/UnitsOffice/HD/MTI/Drugs/ISCP/Documents/OMCL.jpg>
- <sup>410</sup> Ibid.
- <sup>411</sup> Ibid.
- <sup>412</sup> USDA (2015).
- <sup>413</sup> Ibid.
- <sup>414</sup> Ibid.
- <sup>415</sup> WIPO (2015).
- <sup>416</sup> Ministry of Economy and Industry, “ITTN 2015 – 3<sup>rd</sup> Conference of the Israel Tech Transfer Organization”, <http://itrade.gov.il/switzerland/ittn-2015-3rd-conference-of-the-israel-tech-transfer-organization/>
- <sup>417</sup> Yisum Technology Transfer (2011), “Technology Transfer: The Secret Engine Behind Israel’s Success”
- <sup>418</sup> Yeda, “Technology Transfer From The Weizmann Institute Of Science: From Our Pipeline To Your Bottom Line”, <https://ec.europa.eu/jrc/sites/default/files/events/20140120-tto-circle/jrc-20140120-tto-circle-naiberg.pdf>
- <sup>419</sup> Deloitte (2014), “2014 Global Services of R&D Tax Incentives”, p.22, <http://www2.deloitte.com/content/dam/Deloitte/global/Documents/Tax/dttl-tax-global-rd-survey-aug-2014.pdf>
- <sup>420</sup> Israel Tax Authority 2015.
- <sup>421</sup> Calcalist (2015), “Commission Recommendations Revealed: There is no Agreement on Limiting Tax Benefits for Large Companies”, 6/26/2015, <http://www.calcalist.co.il/local/articles/0,7340,L-3662908,00.html>
- <sup>422</sup> Ministry of Economy and Industry, New Amendment Will Encourage Investments from New “Investors by Raising Assurances Regarding Tax Benefits”, 12/30/2015, <http://economy.gov.il/English/NewsRoom/PressReleases/Pages/AmendAngelsLaw.aspx>
- <sup>423</sup> National Health Insurance Act 1994. Text available (in Hebrew) at [http://www.nevo.co.il/law\\_html/Law01/036\\_001.htm#Seif83](http://www.nevo.co.il/law_html/Law01/036_001.htm#Seif83)
- <sup>424</sup> Ministry of Health (2010), “Report of the Committee to Examine Supervision of Drug Pricing”(translated), 09/2010, p.19, <http://linshom.org.il/files/PDF/Supervision.pdf>; Ministry of Health (2011), “Proposal to Reduce Fees of Drugs with a Generic Alternative” (translated), 06/28/2011, pp.6-8, <https://www.knesset.gov.il/mmm/data/pdf/m02886.pdf>
- <sup>425</sup> Times of Israel (2015), “End-Of-Year Reports Rank Israel High On Tech, Low On Infrastructure”, 12/27/2015, <http://www.timesofisrael.com/end-of-year-reports-rank-israel-high-on-tech-low-on-infrastructure/>

- <sup>426</sup> World Economic Forum (2015), p.209.
- <sup>427</sup> Ibid.
- <sup>428</sup> World Bank (2014).
- <sup>429</sup> World Bank, Data bank, GDP per capita (current US\$), Japan.
- <sup>430</sup> World Economic Forum (2015).
- <sup>431</sup> The Japan Times, “Science And Technology Plan”, 2/6/2016,  
<http://www.japantimes.co.jp/opinion/2016/02/06/editorials/science-technology-plan/#.VxIGdZMrI6V>
- <sup>432</sup> Council for Science, Technology and Innovation, Government of Japan (2015), “Report on the 5<sup>th</sup> Science and Technology Basic Plan”, 12/18/2015 (English report).
- <sup>433</sup> Cabinet Office, Japan, “Brochure about the Council for Science, Technology and Innovation 2015”,  
<http://www8.cao.go.jp/cstp/english/panhu/index.html>
- <sup>434</sup> Ibid.
- <sup>435</sup> MEXT, “Towards a Comprehensive Strategy of Science and Technology for the Medium-to-Long Term”,  
[http://www.mext.go.jp/english/science\\_technology/1316764.htm](http://www.mext.go.jp/english/science_technology/1316764.htm)
- <sup>436</sup> OECD, Key Biotech Indicators, 2015.
- <sup>437</sup> OECD, Health at a Glance 2015, p.31.
- <sup>438</sup> Japanese Bioindustry Association (JPA), “2015 Bioventure Statistics and Trends – Survey Report, Overview”.
- <sup>439</sup> Elze, C. & Thuncke, M. (2012), “The Challenge for Japan’s Pharmaceutical Top Twenty: Building on the Lessons of Broken Model”, Catenion.
- <sup>440</sup> OECD (2016), Main Science and Technology Indicators, Volume 2015/2.
- <sup>441</sup> Ministry of Health, Labour and Welfare (MHLW) (2014), “Strategy Of SAKIGAKE: Leading The World In The Practical Application Of Innovative Medical Products And Devices”, June 2014
- <sup>442</sup> Natasha Khan/Bloomberg (2015), “Regenerative Medicine To Get Boost From Deregulation In Japan”, 9/3/2015, <http://www.japantimes.co.jp/news/2015/09/03/national/science-health/regenerative-medicine-get-boost-deregulation-japan/#.V1LDnGblRvd>
- <sup>443</sup> Deloitte (2016), Global Life Science Outlook 2016: Moving Forward with Cautious Optimism”, p.A21.
- <sup>444</sup> MHLW, “Comprehensive Strategy for the Pharmaceutical Sector”, 2015.
- <sup>445</sup> Japan Agency for Medical Research and Development, <http://www.amed.go.jp/en/>
- <sup>446</sup> H. Nakamura (2015), “The Biosciences Industry In Japan: Why And How Does The Government Support A Strategic Sector For The Country”, Health Policy Decision Makers Forum Asia Pacific 2015.
- <sup>447</sup> Pharma Japan, “MHLW Announces Comprehensive Strategy to Beef Up Pharma Industry, Vows to Promote Reward for Innovation”, 9/7/2015.
- <sup>448</sup> Iain M. Cockburn, Jean O. Lanjouw, Mark Schankerman (2014) “Patents and the Global Diffusion of New Drugs”, NBER Working Paper No. 20492, Table A2, p. 43.
- <sup>449</sup> Pugatch Consilium (2016), “Measuring The Global Biomedical Pulse The Biopharmaceutical Investment & Competitiveness (Bci) Survey – 2016”.
- <sup>450</sup> USDA Foreign Agricultural Service(2015), “Japan Agricultural Biotechnology Annual: Japan’s Regulatory System For GE Crops Continues To Improve”, July 2015.
- <sup>451</sup> ISAAA (2015), “ISAAA Brief 51-2015: Executive Summary”; MHLW, Pharmaceutical and Food Dept., Food Safety Sec., Chart of GM Foods and Food Additives that Went Through Safety Examinations.
- <sup>452</sup> See, for instance, Wakasa, Y. et al (2013), “Oral Immunotherapy With Transgenic Rice Seed Containing Destroyed Japanese Cedar Pollen Allergens, Cry J 1 And Cry J 2, Against Japanese Cedar Pollinosis”, *Journal of Plant Biotechnology*, Vol.11, No.11, pp.66-76.
- <sup>453</sup> USDA Foreign Agricultural Service (2015).
- <sup>454</sup> Tanaka, Y. (2013), “Attitude Gaps Between Conventional Plant Breeding Crops And Genetically Modified Crops, And Psychological Models Determining The Acceptance Of The Two Crops”, *Journal of Risk Research*, Vol16, Iss.1.
- <sup>455</sup> A. Dewit, (2015), “Japan’s Bid to Become a World Leader in Renewable Energy”, *The Asia-Pacific Journal*, Vol. 13, Iss.39, No.2.
- <sup>456</sup> Ibid.
- <sup>457</sup> JPA (2015), “2015 Bioventure Statistics”.
- <sup>458</sup> Hirata, S. & Kimura, S. (2014), “IEA Bioenergy: Country Report Japan”, October 2014.
- <sup>459</sup> Stratas Advisors (2015), “Japan: Biofuels Policy & Market”, 12/9/2015.
- <sup>460</sup> Ministry of Agriculture, Forestry and Fisheries (MAFF), “Reference 6: Biomass Policies and Assistance Measures in Japan”.
- <sup>461</sup> Japan Today, “Japan Announces Long-Term Strategy For Green Technology Innovations”, 4/18/2016; Initiatives for Next-generation Aviation Fuels (INAF), Roadmap for Establishing Supply Chain for Next-Generation Aviation Fuel, July 2015.
- <sup>462</sup> Times Higher Education World University Rankings 2015-16: Life Sciences Top 100.
- <sup>463</sup> Ibid. Engineering and technology top 100.
- <sup>464</sup> World Bank, Data bank, Scientific and technical journal articles, IP.JRN.ARTC.SC.
- <sup>465</sup> OECD (2015), “Science, Technology and Industry Scoreboard 2015”, 2.6.1 The quantity and quality of scientific production, 2003-12, OECDstat.
- <sup>466</sup> OECD (2016), p.29.

- <sup>467</sup> Ibid., p.21.
- <sup>468</sup> Ibid.
- <sup>469</sup> Ibid. p.32.
- <sup>470</sup> OECD (2015), “Biotechnology R&D Expenditures In The Business Sector, 2013 Or Latest Available Year”
- <sup>471</sup> NIH/Clinicaltrials.gov
- <sup>472</sup> Ibid.
- <sup>473</sup> Ibid.
- <sup>474</sup> OECDSTAT, Patents by technology, Triadic Patent families, Inventor(s)'s country(ies) of residence, Priority date, Biotechnology.
- <sup>475</sup> Justin Chakma et al/NEJM (2014), “Asia’s Ascent — Global Trends in Biomedical R&D Expenditures”, 1/2/2014, [http://rwjcsponc.edu/downloads/news/2014/20140102\\_NEJM.pdf](http://rwjcsponc.edu/downloads/news/2014/20140102_NEJM.pdf)
- <sup>476</sup> Ibid.
- <sup>477</sup> Japan Bioindustry Association (2015), “A New Age of Bio-Business Toward the Creation of New Industry Clusters: Annual Report 2015”.
- <sup>478</sup> A Groh et al (2015), “Venture Capital & Private Equity Country Attractiveness Index 2015”, IESE and EMLYON.
- <sup>479</sup> Pharmaceutical Affairs Law, 2007.
- <sup>480</sup> Jones Day (2016), “Japan Strengthens Deterrence Measures Against Trade Secret Infringement”, February 2016.
- <sup>481</sup> Japan Today, “Shorter 'drug lag' in Japan leads to faster OK for medicines available in other countries”, 11/29/2015, <http://www.japantoday.com/category/health/view/shorter-drug-lag-in-japan-leads-to-faster-ok-for-medicines-available-in-other-countries>
- <sup>482</sup> IHS, “Japan's MHLW Announces First Batch Of Six Drugs To Receive New Sakigake Fast-Track Designation”, 10/27/2015.
- <sup>483</sup> Deloitte (2016), Global Life Science Outlook 2016: Moving Forward with Cautious Optimism”, p.A21.
- <sup>484</sup> USDA (2015), “Agricultural Biotechnology Annual - Japan”.
- <sup>485</sup> Food Safety Basic Law; Law Concerning the Safety and Quality Improvement of Feed (the Feed Safety Law)
- <sup>486</sup> USDA (2015), p.28.
- <sup>487</sup> The Diplomat (2015), “Can Shinzo Abe Inspire Silicon Valley's Dynamism in Japan?”5/1/2015, <http://thediplomat.com/2015/05/can-shinzo-abe-inspire-silicon-valleys-dynamism-in-japan/>
- <sup>488</sup> Deloitte (2015), “2015 Global Survey of R&D Incentives”, p.27.
- <sup>489</sup> Takayama, A. & Narukawa, M. (2016), “Pharmaceutical Pricing and Reimbursement in Japan For Faster, More Complete Access to New Drugs”, *Therapeutic Innovation & Regulatory Science*, Vol.50, No.3, pp.361-67
- <sup>490</sup> IHS (2015), “Japan's FY2016 Drug-Price Revision Expected At 6.8%, Sakigake-Premium Maximum Raised To 20%”, 12/4/2015, <https://www.ihs.com/country-industry-forecasting.html?ID=10659107654>
- <sup>491</sup> The Pharma Letter, “Japan’s Drug Pricing Authority Hears Opinions From Pharma Industry”, 9/3/2013.
- <sup>492</sup> ZSA Associates, “Re-Pricing Rules in Japan Slash Prices for ‘Huge Sales’ Drugs”, 2/1/2016.
- <sup>493</sup> Pharma Japan, “Chuikyo OKs 7 Drugs Subject to Cost-Effective Review; Re-Pricing to Be Conducted in 2018”, 4/27/2016, <http://pi.iho.jp/servlet/pjh/regulatory/outline/1226584989701.html>
- <sup>494</sup> World Justice Project (2015).
- <sup>495</sup> World Bank (2015), “Republic of Korea: the country at a Glance”, <http://www.worldbank.org/en/country/korea>
- <sup>496</sup> Klaus Schwab/World Economic Forum (2015).
- <sup>497</sup> OECD (2009), “OECD Reviews of Innovation Policy: Korea”, pp. 179-80.
- <sup>498</sup> Biospectrum (2016), “Korean President Rolls Out Plan to Beef Up the Biotech Sector”, 4/28/2016, <http://www.biospectrumasia.com/biospectrum/news/223604/korean-president-rolls-plans-beef-biotech-sector>
- <sup>499</sup> Ibid.
- <sup>500</sup> Ibid.
- <sup>501</sup> GEN News (2016), “Top Eight Asia Biopharma Clusters 2016”, 5/30/2016, <http://www.genengnews.com/insight-and-intelligence/top-eight-asia-biopharma-clusters-2016/77900669/>
- <sup>502</sup> Business Korea (2016), “Korean Gov’t to Create 80B Won Fund to Promote Biotech Startups”, 5/26/2016, <http://www.businesskorea.co.kr/english/news/industry/14799-promotion-bio-startups-korean-gov%E2%80%99t-create-80b-won-fund-promote-biotech-startups>
- <sup>503</sup> Korea Research Institute of Bioscience and Biotechnology (KRIBB), About Us, (Accessed May 2016): <http://www.kribb.re.kr/eng/>
- <sup>504</sup> Ibid.
- <sup>505</sup> Ibid
- <sup>506</sup> Ibid
- <sup>507</sup> KRIBB, News, “KRIBB Company Posted an Export of 57 Mil. USD”, 3/5/2015, (Accessed May 2016): <http://www.kribb.re.kr/eng/>
- <sup>508</sup> Ibid. “It’s the Convergence! KRIBB to Join Forces with the Industry”, September 29 2014, (Accessed May 2016).
- <sup>509</sup> OECDStat.

- <sup>510</sup> Ministry of Food and Drug Safety, Bio Information, (Accessed June 2016), <http://www.mfds.go.kr/eng/index.do?nMenuCode=45>
- <sup>511</sup> Korean Joongang Daily (2016), “Biotech Offers Big Opportunities for Korean Economy”, 2/15/2016, <http://koreajoongangdaily.joins.com/news/article/Article.aspx?aid=3015042>
- <sup>512</sup> Pharmabiz, “Korea to accelerate “Pharma 2020 Vision”, August 21 2014, (Accessed May 2016), <http://www.pharmabiz.com/PrintArticle.aspx?aid=84405&sid=21>
- <sup>513</sup> Ibid.
- <sup>514</sup> PMLive (2013), “An Eye Towards the Bio-better in South Korea”, 03/12/2013, [http://www.pmlive.com/pharma\\_intelligence/an\\_eye\\_towards\\_the\\_biobetter\\_in\\_south\\_korea\\_466459](http://www.pmlive.com/pharma_intelligence/an_eye_towards_the_biobetter_in_south_korea_466459)
- <sup>515</sup> Business Korea (2015), “Government Provide Aggressive Support to Introduce Local Biomedines to Global Market” 03/18/2015, <http://www.businesskorea.co.kr/article/9667/biomedicine-support-system-government-provide-aggressive-support-introduce-local#sthash.w5SUYEKo.dpuf>; Financial Times, (2015), “South Korea Pushes to Be New Force in Pharmaceuticals”, 06/10/2015.
- <sup>516</sup> Financial Times.
- <sup>517</sup> E Palmer (2015), “Samsung Biologics To Expand New Songdo Plant”, 2/17/2015, *FiercePharma Manufacturing*.
- <sup>518</sup> Samsung Biologics (2015), “Samsung Biologics to Construct World's Largest Biopharmaceutical Manufacturing Plant”, 12/22/2015, <https://www.samsungbiologics.com/news/press.do>
- <sup>519</sup> Iain M. Cockburn, Jean O. Lanjouw, Mark Schankerman (2014) “Patents and the Global Diffusion of New Drugs”, NBER Working Paper No. 20492, Table A2, p. 43.
- <sup>520</sup> Pugatch Consilium (2016) “Measuring The Global Biomedical Pulse The Biopharmaceutical Investment & Competitiveness (Bci) Survey – 2016”.
- <sup>521</sup> USDA (2014), “Foreign Agricultural Service, Republic of Korea – Agricultural Biotechnology Annual”, 7/15/2014.
- <sup>522</sup> USDA (2015), “Foreign Agricultural Service, Republic of Korea – Agricultural Biotechnology Annual”, 8/15/2015, p.3.
- <sup>523</sup> Ibid.
- <sup>524</sup> Ibid.
- <sup>525</sup> Ibid.
- <sup>526</sup> Ibid., p.4.
- <sup>527</sup> Ibid.
- <sup>528</sup> KRIBB – Biorefinery Research Center, Objectives, (Accessed June 2016): [http://www.kribb.re.kr/eng/sub02/sub02\\_09\\_01.jsp](http://www.kribb.re.kr/eng/sub02/sub02_09_01.jsp)
- <sup>529</sup> Ibid.
- <sup>530</sup> Biofuels Digest (2016), “South Korean Researchers Develop Method To Produce Biofuels From Human Waste”, 5/31/2016, <http://www.biofuelsdigest.com/bdigest/2016/05/31/south-korean-researchers-develop-method-to-produce-biofuels-from-human-waste/>
- <sup>531</sup> Korean Scientific Cooperation Network with the European Research Area (KORANET), (Accessed June 2016), <http://www.koranet.eu/>
- <sup>532</sup> Biofuels Digest (2016), “South Korea’s GS Caltex to Start Construction on \$44 million Biobutanol Plant in H1”, 3/26/2015, <http://www.biofuelsdigest.com/bdigest/2016/03/24/south-koreas-gs-caltex-to-start-construction-on-44-million-biobutanol-plant-in-h1/>
- <sup>533</sup> Times Higher Education World University Rankings 2015-2016.
- <sup>534</sup> World Bank, Data bank, Scientific and technical journal articles, IP.JRN.ARTC.SC.
- <sup>535</sup> OECD (2015), “Science, Technology and Industry Scoreboard 2015”, 2.6.1 The quantity and quality of scientific production, 2003-12, OECDstat.
- <sup>536</sup> OECD (2016), p.29.
- <sup>537</sup> OECD (2016), p. 21.
- <sup>538</sup> Ibid. p. 32.
- <sup>539</sup> Business Korea (2016).
- <sup>540</sup> NIH/Clinicaltrials.gov
- <sup>541</sup> Ibid.
- <sup>542</sup> OECDSTAT, Patents by technology, Triadic Patent families, Inventor(s)'s country(ies) of residence, Priority date, Biotechnology.
- <sup>543</sup> A Groh et al (2015), “Venture Capital & Private Equity Country Attractiveness Index 2015”, IESE and EMLYON.
- <sup>544</sup> Yoon and Young LLC (2015), “The National Assembly Passed the Amendment to the Pharmaceutical Affairs Act” 03/13/2015, <http://www.lexology.com/library/detail.aspx?g=aa6a96b7-094f-488f-a332-01da4949c588>
- <sup>545</sup> Reinhold Cohn Group (2015) “The Korean Supreme Court Decides That New Medical Use Characterized By A Dosage Regimen Or Dose Is Patentable”, 7/21/2015, <http://www.lexology.com/library/detail.aspx?g=7aecabed-2f13-4a4c-ae47-5d93a7da59b6>
- <sup>546</sup> PP Song et al. (2012), “Rare Diseases, Orphan Drugs, And Their Regulation In Asia: Current Status And Future Perspectives”, *Intractable Rare Dis Res* 1.1 (2012): 3-9.
- <sup>547</sup> PhRMA (2015), Special 301 Submission, p. 64-5.

- 548 PhRMA (2016), Special 301 Submission, p.131.
- 549 Yoon and Young LLC (2015).
- 550 U.S. Food and Drug Administration (2013), “Global Engagement”, p. 15.
- 551 WIPO (2007).
- 552 Ministry of Trade (2009), Industry & Energy, “Technology Transfer and Commercialization Promotion Act”.
- 553 Lee Yoon-jun (2010), “R &D Policy In Korea Bringing University Technologies To Markets”, *Korea Herald*, 3/29/2010.
- 554 WIPO (2015), p.46.
- 555 WIPO (2014), p. 18.
- 556 OECD (2009), p. 117.
- 557 Finance Asia (2015), “Korea Brews Start-Ups For Sustainable Growth”, 11/3/2015, <http://www.financeasia.com/News/403404,korea-brews-start-ups-for-sustainable-growth.aspx>
- 558 OECD (2012), “OECD Science, Technology and Industry Outlook”, p. 338.
- 559 ERAWATCH – Platform on Research and Innovation policies and systems, Korea Institute for Advancement of Technology, (Accessed June 2016), [http://erawatch.jrc.ec.europa.eu/erawatch/opencms/information/country\\_pages/kr/organisation/organisation\\_0009?tab=template&country=kr](http://erawatch.jrc.ec.europa.eu/erawatch/opencms/information/country_pages/kr/organisation/organisation_0009?tab=template&country=kr)
- 560 Deloitte (2015), p. 47.
- 561 The Korea Times (2015), “Foreign Drug Firms Call for Easing Rules on Pricing, Reimbursement”, 02/27/2015, “[http://www.koreatimes.co.kr/www/news/biz/2015/02/123\\_173777.html](http://www.koreatimes.co.kr/www/news/biz/2015/02/123_173777.html); KRPIA (2015), “Pharmaceutical Industry Raises Voice for Frequent System for Reducing Drug Prices”, Press Release, 05/06/2015, [http://members.krpia.or.kr/bbs/bbs\\_view.asp?num=12978&bd\\_gubun=04](http://members.krpia.or.kr/bbs/bbs_view.asp?num=12978&bd_gubun=04)
- 562 IHS (2012), “Pharmaceutical Price Cuts in South Korea in 2013”, 12/27/2012, <http://blog.ihs.com/pharmaceutical-price-cuts-in-south-korea-in-2013>; PhRMA (2015), “301 Special Submission Report”, p. 67-68; EC/DG TRADE Market Access Database, “Pricing of Pharmaceutical and Medical Devices – Korea”, [http://madb.europa.eu/madb/barriers\\_details.htm?barrier\\_id=135438&version=1](http://madb.europa.eu/madb/barriers_details.htm?barrier_id=135438&version=1)
- 563 PharmaAsia News (2013), “South Korea Mulls Revision Of Price Volume Agreement, Stoking Opposition Across Industry”, 05/13/2013, <https://www.pharmamedtechbi.com/publications/pharmasia-news/2013/5/28/south-korea-mulls-revision-of-price-volume-agreement-stoking-opposition-across-industry>
- 564 IHS (2015), “South Korea's Pharma Industry Lobbies Against Planned Drug Price Cuts”, 09/09/2015, <https://www.ihs.com/country-industry-forecasting.html?ID=10659105466>
- 565 The World Justice Project (2015).
- 566 World Bank (2015).
- 567 World Bank, Data bank, GDP per capita (current US\$).
- 568 World Economic Forum (2016), p. 6.
- 569 World Bank, (2010), What is New in Malaysia’s New Economic Model?”.
- 570 11th Malaysia Plan Anchoring Growth to People, p.266.
- 571 Ibid.
- 572 Biotechcorp (2014), “Annual Report 2014”, p. 1.
- 573 BiotechCorp Annual Report 2015, p.28.
- 574 Ibid., p.12.
- 575 MOSTI, Biotechnology Cluster, (Accessed May 2016), <http://www.mosti.gov.my/en/cluster/bioteknologi/>
- 576 MOSTI, National Biotechnology Division (BIOTEK), (Accessed May 2016), <http://www.mosti.gov.my/en/about-us/divisions-departments/national-biotechnology-division-biotek/>
- 577 MOSTI, Genome Malaysia, (Accessed May 2016), <http://www.genomemalaysia.gov.my/v3/>
- 578 Malaysian Institute of Pharmaceutical and Nutraceuticals, About IPHARM, (Accessed May 2016), <http://www.ipharm.gov.my/2014/index.php/about-ipharm.html>
- 579 Agro-Biotechnology Institute, About Us, (Accessed May 2016), <http://www.abi-nibm.my/index.php/about>
- 580 InnoBio, About Us, (Accessed May 2016), [http://www.innobio.com/?page\\_id=5](http://www.innobio.com/?page_id=5)
- 581 MOSTI, About TPM, (Accessed May 2016), <http://www.tpm.com.my/about/ab.php>
- 582 Ibid.
- 583 BioTechCorp, Products and Technology, (Accessed May 2016), <http://www.biotechcorp.com.my/products-technology/>
- 584 Ibid.
- 585 Biotech Corp (2014), pp. 46-7.
- 586 S Las Marias (2013), “Agila Biotech to Set Up Biotech Facility at Malaysia's Bio-XCell Ecosystem”, *Pharma Asia*, 3/21/2013.
- 587 BioSpectrum (2015), “Biocon Malaysia’s Plant to Begin Operation Next Year”, 7/8/2015, <http://www.biospectrumasia.com/biospectrum/news/221819/biocons-malaysia-plant-begin-operations>
- 588 J. Chin (2014), “Biologics to Raise CCM Duopharma's Profile”, 2/22/2014, *The Star Online*.
- 589 Ibid.
- 590 Rajah & Tann Singapore LLP (2016), “Malaysian Parliament Assents to Transpacific Trade Partnership - What About the Rest?”, 2/5/2016, <http://www.lexology.com/library/detail.aspx?g=db6f3eec-bf1d-449e-8139-a614e3dbb150>



- <sup>591</sup> Iain M. Cockburn, Jean O. Lanjouw, Mark Schankerman (2014) “Patents and the Global Diffusion of New Drugs”, NBER Working Paper No. 20492, Table A2, p. 43.
- <sup>592</sup> Ibid. p. 8.
- <sup>593</sup> Ibid.
- <sup>594</sup> The Star online (2016), “Malaysia Raises April Palm Oil Export Duty To 5%”, 3/15/2016, <http://www.thestar.com.my/business/business-news/2016/03/15/malaysia-raises-april-palm-oil-export-duty-to-5pct/>
- <sup>595</sup> USDA (2015), “Malaysia Biofuels Annual”, p.1, 9/9/2015.
- <sup>596</sup> The Star online (2016), “B10 Biodiesel Programme on Course”, 3/8/2016, <http://www.thestar.com.my/business/business-news/2016/03/08/b10-biodiesel-programme-on-course/>
- <sup>597</sup> USDA (2015), “Malaysia Agricultural Biotechnology Annual”, p.1, 7/10/2015.
- <sup>598</sup> Ibid.
- <sup>599</sup> Times Higher Education World University Rankings 2015-2016.
- <sup>600</sup> Ibid. BRICS and emerging economies rankings 2015.
- <sup>601</sup> World Bank, Data bank, Scientific and technical journal articles, IP.JRN.ARTC.SC.
- <sup>602</sup> World Bank, World Development Indicators: Science and Technology.
- <sup>603</sup> World Bank, Research and Development Expenditure (% of GDP).
- <sup>604</sup> OECD (2014), p. 21.
- <sup>605</sup> Clinicaltrials.gov, (Accessed June 2016), <https://clinicaltrials.gov/ct2/search/map/click?map.x=556&map.y=215>
- <sup>606</sup> Ibid.
- <sup>607</sup> OECDStat, Patents by technology, Triadic Patent families, Inventor(s)'s country(ies) of residence, Priority date, Biotechnology.
- <sup>608</sup> A Groh et al (2015), “Venture Capital & Private Equity Country Attractiveness Index 2015”, IESE and EMLYON.
- <sup>609</sup> National Pharmaceutical Control Board, About the Drug Control Authority, (Accessed June 2016), <http://portal.bpfk.gov.my/index.cfm?&menuid=148&parentid=9>
- <sup>610</sup> PhRMA (2015), pp. 139-140.
- <sup>611</sup> Ibid.
- <sup>612</sup> USDA (2015), “Agricultural Biotechnology Annual – Malaysia”.
- <sup>613</sup> AM Azmi (2014), “Intellectual Property Policy and Academic Patenting In Malaysia: Challenges and Prospects” *Pertanika J. Soc. Sci. & Hum.* 22 (S): 1 - 20 (2014), p. 6.
- <sup>614</sup> Ibid. pp. 4-5.
- <sup>615</sup> Ibid.
- <sup>616</sup> Academy of Sciences, p.61.
- <sup>617</sup> The National University of Malaysia, Centre for Collaborative Innovation – Technology Transfer, (Accessed June 2016), [http://www.ukm.my/pik/index.php?option=com\\_content&view=article&id=115&Itemid=242](http://www.ukm.my/pik/index.php?option=com_content&view=article&id=115&Itemid=242)
- <sup>618</sup> BioTechCorp, (2011), “Guidelines on the Process & Procedures for Bionexus Status Application”, p. 2.
- <sup>619</sup> Deloitte, (2015), “Global Survey of R&D Tax Incentives”, p. 29.
- <sup>620</sup> Ibid.
- <sup>621</sup> Ibid.
- <sup>622</sup> PharmaPhorum, (2014), “Malaysia Pharmaceutical Market Update 2014”, (Accessed May 2016): <http://www.pharmaphorum.com/articles/malaysia-pharmaceutical-market-update-2014>
- <sup>623</sup> PhRMA (2015), p. 139.
- <sup>624</sup> Ibid., p.143.
- <sup>625</sup> WJP, (2015), p.114.
- <sup>626</sup> World Bank website (accessed May 2016), “Mexico overview”, <http://www.worldbank.org/en/country/mexico>
- <sup>627</sup> Ibid.
- <sup>628</sup> Klaus Schwab/World Economic Forum (2015), p.31.
- <sup>629</sup> L. R. Leon (2012), “Erawatch country reports 2012: Mexico. (Country Report)”, Belgium: Erawatch Network - Technopolis Group Belgium, p. 11.
- <sup>630</sup> OECD (2013), p. 41.
- <sup>631</sup> Ibid.
- <sup>632</sup> Ibid., 42.
- <sup>633</sup> Ibid., 47.
- <sup>634</sup> OECD (2014), “STI Outlook”, p. 118.
- <sup>635</sup> OECDStat, Key Biotech Indicators, Number of firms active in biotechnology, 2011 or latest available year, July 2015.
- <sup>636</sup> OECDStat, Key Biotech Indicators, Biotechnology R&D expenditures in the business sector, 2011 or latest available year, Millions of USD PPP, July 2015.
- <sup>637</sup> Ibid.
- <sup>638</sup> OECDStat, Biotechnology R&D intensity in the business sector, 2011 or latest available year, Biotechnology R&D in the business enterprise sector as a percentage of industry value added.
- <sup>639</sup> Ministry of Economy (2013), “The Pharmaceutical Industry”, *ProMexico, Trade and Investment*, p. 15.

- <sup>640</sup> Ibid.
- <sup>641</sup> Ibid.
- <sup>642</sup> Flinn Foundation, “FDA Grants Approval To Scorpion Antivenom Tested By UA Team”, Arizona Biosciences News, 8/12/2011; Instituto Bioclon, “Who we are”, (Accessed May 2016), [http://www.bioclon.com.mx/bioclon/html/quienes\\_en.html](http://www.bioclon.com.mx/bioclon/html/quienes_en.html)
- Mexico business blog, “Recent Developments In Biotechnology In Mexico”, 11/18/2011, (Accessed May 2016): <http://bdp-americas.com/blog/2011/11/18/recent-developments-in-biotechnology-in-mexico/>
- <sup>643</sup> BioPharma (2015), Mexican Scorpion Research Could Yield Cancer and Parkinson Disease”, <http://www.biopharma-reporter.com/Bio-Developments/Mexican-scorpion-research-could-yield-cancer-and-Parkinson-s-disease-drugs>
- <sup>644</sup> PhRMA (2016).
- <sup>645</sup> BioPharmaDive (2015), “Sanofi Scores Landmark Approval For World's 1st Dengue Vaccine In Mexico”, 12/10/2015, <http://www.biopharmadive.com/news/sanofi-scores-landmark-approval-for-worlds-1st-dengue-vaccine-in-mexico/410616/>
- <sup>646</sup> Iain M. Cockburn, Jean O. Lanjouw, Mark Schankerman (2014) “Patents and the Global Diffusion of New Drugs”, NBER Working Paper No. 20492, Table A2, p. 43.
- <sup>647</sup> Pugatch Consilium (2016), “Measuring The Global Biomedical Pulse The Biopharmaceutical Investment & Competitiveness (Bci) Survey – 2016”.
- <sup>648</sup> USDA (2014), “Agricultural Biotechnology Annual, Mexico”, p. 6.
- <sup>649</sup> Ibid.
- <sup>650</sup> Ibid.
- <sup>651</sup> G Guerra (2014), “Restrictions On Genetically Modified Organisms: Mexico”, Law library of US Congress, March 2014, (Accessed May 2016), <http://www.loc.gov/law/help/restrictions-on-gmos/mexico.php>
- <sup>652</sup> Ibid.
- <sup>653</sup> CIBIOGEM, “Results of Projects Funded by background CIBIOGEM” (Accessed May 2016), <http://www.conacyt.gob.mx/cibiogem/index.php/resultados-proyectos-financiados-fondo-cibiogem>
- <sup>654</sup> ISAA (2015), p. 2.
- <sup>655</sup> USDA (2015), “Agricultural Biotechnology Annual, Mexico”, p. 2.
- <sup>656</sup> Ibid.
- <sup>657</sup> Financial Times (2016), “Agribusiness Eyes Mexico as Courts Debate lifting GM Maize Ban”, 1/14/2016, <http://www.ft.com/intl/cms/s/2/d090d12a-9a9e-11e5-a5c1-ca5db4add713.html#axzz49C6XtAE5>; La Jornada de Oriente (2016), “GM Corn Won't Be Produced, Scientists Win Over Monsanto”, 3/8/2016, <http://www.lajornadadeoriente.com.mx/2016/03/08/maiz-transgenico-no-sera-sembrado-cientificos-le-ganan-monsanto/>
- <sup>658</sup> Mexico News Daily (2015), “GMO Opponents Win Another Round”, 11/7/2015, <http://mexiconewsdaily.com/news/gmo-opponents-win-another-round/>
- <sup>659</sup> USDA (2009), “GAIN Mexico Biofuels Annual”, p. 2.
- <sup>660</sup> BP (2015), p. 39.
- <sup>661</sup> Reuters (2015), “Mexico's Pemex Launches Ethanol Biofuel Program To Cut Emissions”, 3/20/2015.
- <sup>662</sup> Pemex, Press Release, “Pemex signs contracts for the acquisition of anhydrous ethanol”, 4/8/2015.
- <sup>663</sup> Times Higher Education World University Rankings 2015-2016.
- <sup>664</sup> OECStat, Education Statistics, Graduates by Field of Education, Life Sciences.
- <sup>665</sup> World Bank, Data bank, Scientific and technical journal articles, IP.JRN.ARTC.SC.
- <sup>666</sup> OECD (2015), “Science, Technology and Industry Scoreboard 2015”, 2.6.1, The quantity and quality of scientific production, 2003-12, OECStat.
- <sup>667</sup> OECD (2016), p.29.
- <sup>668</sup> CONACYT (2016), “Mexico Improves in STI: Enrique Cabrero”, 1/28/2016, <http://www.conacytprensa.mx/index.php/sociedad/politica-cientifica/5221-avanza-mexico-en-ciencia-tecnologia-e-innovacion-enrique-cabrero>
- <sup>669</sup> OECD (2015).
- <sup>670</sup> NIH/Clinicaltrials.gov
- <sup>671</sup> Ibid.
- <sup>672</sup> OECDSTAT, Patents by technology, Triadic Patent families, Inventor(s)'s country(ies) of residence, Priority date, Biotechnology.
- <sup>673</sup> A Groh et al (2015), “Venture Capital & Private Equity Country Attractiveness Index 2015”, IESE and EMLYON.
- <sup>674</sup> WireNews (2013), "Mexico Pharmaceuticals & Healthcare Report Q2 2013", (Accessed May 2016): <http://www.wirenews.co.uk/mexico/healthcare/9185/mexico-pharmaceuticals-healthcare-report-q2-2013-now-available-at-fast-market-research>
- <sup>675</sup> BMI Research (2014), “COFEPRIS Shortens Pre-Approval Time For Clinical Trials”, 3/17/2014, (Accessed May 2016), <http://www.bmiresearch.com/news-and-views/cofepris-shortens-pre-approval-time-for-clinical-trials#sthash.rCBIOe4S.dpuf>
- <sup>676</sup> Ibid.
- <sup>677</sup> USDA (2012), “Agricultural Biotechnology Annual – Mexico”.

- <sup>678</sup> L Vargas-Parada & E Vance (2013), “Mexico Bolsters Science Funding”, *Nature*, 11/21/2013, VOL 503, 319.
- <sup>679</sup> GD Graff (2007), “Echoes of Bayh-Dole? A Survey of IP and Technology Transfer Policies in Emerging and Developing Economies”. *Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices* (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A.
- <sup>680</sup> H Chagoya (2012), “Technology Transfer Offices: A Boost To Licensing In Mexico”, *Intellectual Asset Management*.
- <sup>681</sup> Ibid.
- <sup>682</sup> H Necoechea et al (2013), “A Conceptual Model Of Technology Transfer For Public Universities In Mexico”, *Journal of Technology Management Innovation*, 8(4), 1388; 24-35.
- <sup>683</sup> Ibid.
- <sup>684</sup> Deloitte (2015), “2015 Global Survey of R&D Tax Incentives”, p. 34.
- <sup>685</sup> CONACYT, Innovation Support Program, <http://www.conacyt.mx/index.php/fondos-y-apoyos/programa-de-estimulos-a-la-innovacion>
- <sup>686</sup> CONACYT (2016).
- <sup>687</sup> Ibid.
- <sup>688</sup> PhRMA (2014), p. 200.
- <sup>689</sup> World Justice Project (2015).
- <sup>690</sup> Ibid. p. 52.
- <sup>691</sup> World Bank Data (2015).
- <sup>692</sup> Ibid.
- <sup>693</sup> Klaus Schwab/World Economic Forum (2015).
- <sup>694</sup> Ministry of Economic Development (2011), “Strategy for Innovative Development of the Russian Federation 2020”, 12/8/2011.
- <sup>695</sup> Ibid.
- <sup>696</sup> ERAWATCH, “Russian Federation: Policy Documents” (Accessed May 2016), [http://erawatch.jrc.ec.europa.eu/erawatch/opencms/information/country\\_pages/ru/policydocument/policydoc\\_0007](http://erawatch.jrc.ec.europa.eu/erawatch/opencms/information/country_pages/ru/policydocument/policydoc_0007)
- <sup>697</sup> Agency for Strategic Initiatives, National Technology Initiative (accessed June 2016), <https://asi.ru/eng/nti/>
- <sup>698</sup> Rusventure (2015), “Composition of First Working Groups to Develop Road Maps of National Technology Initiative Approved”, Press Release, 8/3/2015, <http://www.rusventure.ru/en/press-service/news/detail.php?ID=57091>
- <sup>699</sup> Rusventure (2016), “Foresight Fleet 2016 Introduced 70 Projects For NTI Strategy”, 5/30/2016, <http://www.rusventure.ru/en/press-service/news/detail.php?ID=65083>
- <sup>700</sup> Business Russia (2016), “Alexey Repik Presented a Road Map HealthNet, Developed by the STI”, 6/3/2016, <http://www.deloros.ru/aleksej-repik-predstavil-dorozhnyuy-kartu-healthnet-razrabotannuyu-v-ramkah-nacionalnoj-tehnologicheskoy-iniciativy.html>
- <sup>701</sup> Russian Foundation for Basic Research, (Accessed May 2016), <http://www.rfbr.ru/rffi/ru/>
- <sup>702</sup> Foundation for Assistance to Small Enterprises, (Accessed May 2016), <http://www.fasie.ru/>
- <sup>703</sup> Russian Foundation for Technological Development, (Accessed May 2016), <http://www.rfr.ru/>
- <sup>704</sup> RBC/Netreba (2015), “16% Spending Cuts”, <http://www.rbc.ru/newspaper/2015/05/21/56bcd92e9a7947299f72bfde>
- <sup>705</sup> Embassy of Switzerland in Russia, “Pharma 2020: The Strategy of Development of the Pharmaceutical Industry of the Russian Federation – Analytical Summary”, [http://www.s-ge.com/de/filefield-private/files/25703/field\\_blog\\_public\\_files/5244](http://www.s-ge.com/de/filefield-private/files/25703/field_blog_public_files/5244); Russian Government, “State Coordination Program for the Development of Biotechnology in the Russian Federation until 2020: Summary”, [http://owwz.de/fileadmin/Biotechnologie/Information\\_Biotech/BIO\\_Booklet\\_Block\\_A4\\_CS4.pdf](http://owwz.de/fileadmin/Biotechnologie/Information_Biotech/BIO_Booklet_Block_A4_CS4.pdf)
- <sup>706</sup> Ibid., p.12.
- <sup>707</sup> Rusnano, “Rusnano Corporation”, (Accessed May 2016), <http://en.rusnano.com/about>
- <sup>708</sup> Russian Venture Company, “RVC Biofund”, (Accessed May 2016), <http://www.rusventure.ru/en/investments/biofund/index.php>
- <sup>709</sup> Government of the Russian Federation, Summary – State Coordination Program for the Development of Biotechnology in the Russian Federation Until 2020 (BIO 2020), 2012, p. 12.
- <sup>710</sup> Ibid, p.16.
- <sup>711</sup> Embassy of Switzerland in Russia, p. 7.
- <sup>712</sup> Consult Pharma, (2010), “Russian Federation law No. 61”, (Accessed May 2016), <http://www.consultpharma.ru/index.php/en/documents/drugs/152-61fz?showall=1>
- <sup>713</sup> Dubevoise & Plimpton LLP, (2013), “Recent Developments in the Russian Pharmaceutical”, *Lexology*, 5/31/2013, <http://www.lexology.com/library/detail.aspx?g=7fe187d5-6a21-4874-b79d-d7634dca76ae>
- <sup>714</sup> Deloitte, (2013), “Trends and Practical Aspects of Development of the Russian Pharmaceutical Market”, p. 6.
- <sup>715</sup> Text available (in Russian) at <http://government.consultant.ru/documents/3702867?items=1&page=2>
- <sup>716</sup> MedLinks (2015), “National Immunobiological Company Chosen as Sole Provider of the Ministry of Health”, 6/25/2015, <http://www.medlinks.ru/article.php?sid=64159>
- <sup>717</sup> The Pharma Letter (2016), “Global Insulin Majors May Lose Russian Market Due To New State Monopoly”, 12/10/2015.

- <sup>718</sup> Government Resolution “On Adoption of Rules for Subsidizing to Russian Companies in order to Compensate Part of Expenses for Projects Associated with Manufacturing of Pharmaceuticals and (or) Pharmaceuticals Substances under the Subprogram “Development of Pharmaceuticals Production” of the State program “Development of Pharmaceutical and Medical Industry for 2013 – 2020”. See Vademec (2015), “Ministry of Industry and Trade Developed a Procedure to Provide Subsidies to Producers of Medicines” (translated), 10/27/2015, <http://www.vademec.ru/news/detail75274.html>, KPMG (2015), “KPMG Pharma Bulletin Issue #10, 2015”, October 2015, [http://www.kpmg.com/RU/en/industry/Healthcare\\_and\\_Pharmaceuticals/pharma-bulletin/pharma-bulletin-2015/Pages/Pharma-Issue10-2015.aspx#P\\_1\\_1](http://www.kpmg.com/RU/en/industry/Healthcare_and_Pharmaceuticals/pharma-bulletin/pharma-bulletin-2015/Pages/Pharma-Issue10-2015.aspx#P_1_1)
- <sup>719</sup> Vedomosti (2016), “FAS Proposes to Extend the Production of Drugs Without Consent from Patent Holders”, 3/1/2016, <https://www.vedomosti.ru/economics/articles/2016/03/01/631916-fas-podelit-intellektualnuyu-sobstvennost>
- <sup>720</sup> Ibid.
- <sup>721</sup> The PharmaLetter (2016), “Russia Postpones Compulsory Licensing of Imported Drugs until December”, 5/10/2016, <http://www.thepharmaletter.com/article/russia-postpones-compulsory-licensing-of-imported-drugs-until-december>; The PharmaLetter (2016), “Russia Designs Scheme For Compulsory Licensing Of Imported Drugs”, 4/5/2016, <http://www.thepharmaletter.com/article/russia-designs-scheme-for-compulsory-licensing-of-imported-drugs>
- <sup>722</sup> Iain M. Cockburn, Jean O. Lanjouw, Mark Schankerman (2014) “Patents and the Global Diffusion of New Drugs”, NBER Working Paper No. 20492, Table A2, p. 43.
- <sup>723</sup> Pugatch Consilium (2016), “Measuring The Global Biomedical Pulse The Biopharmaceutical Investment & Competitiveness (Bci) Survey – 2016”.
- <sup>724</sup> Government of the Russian Federation (2012), “State Coordination Program for the Development of Biotechnology in the Russian Federation”, 2012, Report Number: VP-P8 322, p. 27.
- <sup>725</sup> USDA (2014), “The Russian Federation – Agricultural Biotechnology Annual 2014”, Report Number: RS1444
- <sup>726</sup> RT.com (2014), “Russia Postpones Planting of GMOs by 3 Years”, 4/23/2014, <http://rt.com/news/154032-russia-gmo-food-ban/>
- <sup>727</sup> The Moscow Times (2015), “Russia to Ban Genetically Modified Organisms in Food Production”, 9/20/2015, <http://www.themoscowtimes.com/business/article/russia-to-ban-genetically-modified-organisms-in-food-production/531823.html>
- <sup>728</sup> Global Research (2016), “Russia Bans US GMO Import”, 2/26/2016, <http://www.globalresearch.ca/russia-bans-us-gmo-imports/5510933>
- <sup>729</sup> USDA (2015), “Agricultural Biotechnology Annual”, 7/10/2015, [http://gain.fas.usda.gov/Recent%20GAIN%20Publications/Agricultural%20Biotechnology%20Annual\\_Moscow\\_Russian%20Federation\\_7-9-2015.pdf](http://gain.fas.usda.gov/Recent%20GAIN%20Publications/Agricultural%20Biotechnology%20Annual_Moscow_Russian%20Federation_7-9-2015.pdf)
- <sup>730</sup> Ibid.
- <sup>731</sup> RBTH (2015), “Mutants on the March - Purple Potatoes, and Frost-Resistant Oysters”, 9/25/2016, [http://rbth.com/science\\_and\\_tech/2015/09/25/russian\\_mutants\\_on\\_the\\_march\\_-\\_purple\\_potatoes\\_and\\_frost-re\\_49563.html](http://rbth.com/science_and_tech/2015/09/25/russian_mutants_on_the_march_-_purple_potatoes_and_frost-re_49563.html)
- <sup>732</sup> One Nucleus Blog (2016), “Russian Biotech: Bringing Opportunities and Seeking Collaborations”, 4/15/2016, <https://onenucleus.wordpress.com/2016/04/15/russian-biotech-bringing-opportunities-and-seeking-collaborations/>
- <sup>733</sup> Government of the Russian Federation, Summary – State Coordination Program, p. 16.
- <sup>734</sup> USDA (2014), “Biofuels Annual, Russian Federation”, p. 7.
- <sup>735</sup> BP (2015), p. 39.
- <sup>736</sup> USDA (2015), “Biofuels Annual, Russian Federation”, p. 1.
- <sup>737</sup> Times Higher Education World University Rankings 2015-2016.
- <sup>738</sup> World Bank, Data bank, Scientific and technical journal articles.
- <sup>739</sup> OECD (2015), *Science, Technology and Industry Scoreboard 2015*, 2.6.1, The quantity and quality of scientific production, 2003-12, OECDstat.
- <sup>740</sup> OECD (2016), p.29.
- <sup>741</sup> OECD (2016), Gross domestic spending on R&D (indicator). doi: 10.1787/d8b068b4-en (Accessed May 2016)
- <sup>742</sup> Ibid.
- <sup>743</sup> OECD (2015), pp.33.
- <sup>744</sup> Ibid., p.37.
- <sup>745</sup> OECD (2015), “Key Biotechnology Indicators”.
- <sup>746</sup> Ibid.
- <sup>747</sup> NIH/Clinicaltrials.gov
- <sup>748</sup> Ibid.
- <sup>749</sup> OECDSTAT, Patents by technology, Triadic Patent families, Inventor(s)'s country(ies) of residence, Priority date, Biotechnology.
- <sup>750</sup> Skolkovo Foundation, Biomed cluster, <https://sk.ru/foundation/biomed/p/results.aspx>
- <sup>751</sup> One Nucleus Blog (2016).
- <sup>752</sup> Skolkovo (2015), “Annual Report 2015”, [http://sk.ru/foundation/results/annual\\_reports\\_en/](http://sk.ru/foundation/results/annual_reports_en/)
- <sup>753</sup> K Avramov (2014), “Western Sanctions, Russia’s Pivot East, and the Innovation Crisis”, *Center on Global Interests*, 10/10/2014.

- <sup>754</sup> Foreign Policy (2015), “The Short Life and Speedy Death of Russia’s Silicon Valley”, 5/6/2015, <http://foreignpolicy.com/2015/05/06/the-short-life-and-speedy-death-of-russias-silicon-valley-medvedev-go-russia-skolkovo/>
- <sup>755</sup> University World News (2016), “Science Centre To Be Hybrid Of Harvard And Silicon Valley”, 3/31/2016, <http://www.universityworldnews.com/article.php?story=20160331114611744>
- <sup>756</sup> A Groh et al (2015), “Venture Capital & Private Equity Country Attractiveness Index 2015”, IESE and EMLYON.
- <sup>757</sup> WIPO (2011), “Federal Service for Intellectual Property, Patents and Trademarks (ROSPATENT) Russian Federation: Exceptions and Limitations”, (Accessed May 2016), <http://www.wipo.int/scp/en/exceptions/replies/russia.html>
- <sup>758</sup> The Pharma Letter, “Novartis Criticizes System Of Public Procurement Tenders In Russia”, 9/28/2012, <http://www.thepharmalatter.com/article/novartis-criticizes-system-of-public-procurement-tenders-in-russia>
- <sup>759</sup> See: Baker & McKenzie (2015), “Significant Changes to the Law on Circulation of Medicines Will Come into Force in 2015”, Legal Alert, January 2015; and A Gorodissky & Partners (2015), “Overview of Changes to Laws Governing Circulation of Medicinal Products”, April 2015.
- <sup>760</sup> Ibid.
- <sup>761</sup> See: BMI Research (2015), “Novartis IP Infringement Case To Test Multinationals’ Resolve”, 3/31/2015; Marchmontnews (2015), “Court Rules In Favor Of Russian Drug Registration, Dismisses Novartis’ Rights Infringement Complaint”, 4/16/2015; Vegas Lex (2015), “Russian Court Considered Its First Data Exclusivity Case: Implications For Pharmaceutical Manufacturers”, April 2015.
- <sup>762</sup> RegBrug (2016), “Russian GMP Inspection Of Pharmaceutical Manufacturers”, February 2016, <http://www.regdrug.com/russian-gmp-inspection-of-pharmaceutical-manufacturers>
- <sup>763</sup> Chemrar (2016), “Ministry Of Industry Does Not Support The Abolition Of The Foreign Drug Research”, 2/20/2016, [http://www.chemrar.ru/eng/i-news/index.php?ELEMENT\\_ID=20766](http://www.chemrar.ru/eng/i-news/index.php?ELEMENT_ID=20766)
- <sup>764</sup> The Moscow Times (2015), “Russia to Ban Genetically Modified Organisms in Food Production”, 9/20/2015, <http://www.themoscowtimes.com/business/article/russia-to-ban-genetically-modified-organisms-in-food-production/531823.html>
- <sup>765</sup> USDA (2014), “The Russian Federation...”
- <sup>766</sup> US-Russia Innovation Corridor, “Federal Law 217: Commercializing University Research”, (Accessed May 2016), <http://www.usric.org/law-217.html>
- <sup>767</sup> Mikhail A. Gershman, Galina A. Kitova National Research Universities/Higher School of Economics (2016), “Evaluation Of Research And Innovation Policies: The Case Of Russian Universities” *Basic research program working papers, science, technology and innovation*, <https://www.hse.ru/data/2016/01/18/1135141709/57STI2016.pdf>
- <sup>768</sup> Pavel Koshkin (2015), “How Russia Can Overcome Its Innovation Challenges”, 11/11/2015, <http://www.russia-direct.org/qa/how-russia-can-overcome-its-innovation-challenges>
- <sup>769</sup> Ibid.
- <sup>770</sup> Russian Technology Transfer Network, “About RTTN”, (Accessed May 2016), <http://transfer.nichost.ru/about?lang=eng>
- <sup>771</sup> WIPO (2011), *World Intellectual Property Report: The Changing Face of Innovation*, WIPO Economics and Statistics Series, p.149.
- <sup>772</sup> WIPO (2015).
- <sup>773</sup> Deloitte (2014), p. 39.
- <sup>774</sup> PwC (2016), “Summary Of Key Changes In Tax Legislation”, *Issue No. 1*, January 2016, <http://www.pwc.ru/en/tax-consulting-services/assets/legislation/tax-flash-report-2016-1-eng.pdf>
- <sup>775</sup> Resolution of 15 September 2015 N. 979; Vegas Lex (2015), “Legislative Update March-April 2015”, <http://old.vegaslex.ru/en/text/83189>
- <sup>776</sup> World Justice Project (2015), p.20.
- <sup>777</sup> World Bank Data (2015).
- <sup>778</sup> World Bank (2014), “Doing Business 2015: Going Beyond Efficiency”, 10/29/2014, <http://www.doingbusiness.org/rankings>
- <sup>779</sup> Klaus Schwab/World Economic Forum (2015).
- <sup>780</sup> Asian Scientist (2016) “RIE2020: What You Need To Know About Singapore’s Blockbuster \$19b R&D Budget”, 1/11/2016.
- <sup>781</sup> OECD (2013), “Singapore: Innovation Profile”, *Innovation in Southeast Asia*, OECD Publishing, pp. 237-8.
- <sup>782</sup> A\*STAR, “Research Institutes”, (Accessed June 2016), <https://www.a-star.edu.sg/Research/Research-Institutes-Capabilities/Browse-By-Research-Institutes.aspx>
- <sup>783</sup> EDB (2015), “Year 2015 in Review”, 2/6/2016.
- <sup>784</sup> KPMG (2016), “Growing Singapore’s Biomedical R&D”, Tax Alert Issue 10, March 2016.
- <sup>785</sup> EDB (2014), “Biomedical Sciences Singapore The Biopolis of Asia”, EDB Singapore.
- <sup>786</sup> EDB, “Industries”, (Accessed June 2016), <https://www.edb.gov.sg/content/edb/en/industries/industries/pharma-biotech.html>
- <sup>787</sup> EDB (2015), “Singapore Biotech Guidelines 2014/15”.

- <sup>788</sup> EDB, “Pharmaceuticals and Biotechnology” (accessed May 2016), <https://www.edb.gov.sg/content/edb/en/industries/industries/pharma-biotech.html>
- <sup>789</sup> EDB (2015), Singapore Biotech Guidelines 2014/15.
- <sup>790</sup> EDB (2014), Singapore Biotech Guidelines 2013/14.
- <sup>791</sup> Singapore Ministry of Health, Research Grant – Clinician Scientist Award (Accessed June 2016): [http://www.nmrc.gov.sg/content/nmrc\\_internet/home/grant/talentdev/csa.html](http://www.nmrc.gov.sg/content/nmrc_internet/home/grant/talentdev/csa.html)
- <sup>792</sup> Ministry of Health/National Medical Research Council website (accessed June 2016), “Translational & Clinical Research (TCR) Flagship Program Grant”, [http://www.nmrc.gov.sg/content/nmrc\\_internet/home/grant/compgrants/edg1111.html](http://www.nmrc.gov.sg/content/nmrc_internet/home/grant/compgrants/edg1111.html)
- <sup>793</sup> Ibid.
- <sup>794</sup> Belgian Foreign Trade Agency, “Biomedical Science Sector in Singapore”, [http://www.abh-ace.be/sites/default/files/downloads/BFTA%20-%20Biomedical%20Sciences%20Sector%20in%20Singapore\\_nl.pdf](http://www.abh-ace.be/sites/default/files/downloads/BFTA%20-%20Biomedical%20Sciences%20Sector%20in%20Singapore_nl.pdf)
- <sup>795</sup> National Research Foundation, Competitive Research Programme, (Accessed June 2016), <http://www.nrf.gov.sg/about-nrf/programmes/competitive-research-programme>
- <sup>796</sup> National Research Foundation, Competitive Research Programme List of Awarded CRP Projects, (Accessed June 2016), <http://www.nrf.gov.sg/docs/default-source/default-document-library/list-of-projects-that-have-been-awarded.pdf?sfvrsn=0>
- <sup>797</sup> SCRI website (accessed June 2016), <http://www.scri.edu.sg/scri/>; CSI website (accessed June 2016), <https://www.csi.nus.edu.sg/ws/>
- <sup>798</sup> Iain M. Cockburn, Jean O. Lanjouw, Mark Schankerman (2014) “Patents and the Global Diffusion of New Drugs”, NBER Working Paper No. 20492, Table A2, p. 43.
- <sup>799</sup> Pugatch Consilium (2016) “Measuring The Global Biomedical Pulse The Biopharmaceutical Investment & Competitiveness (Bci) Survey – 2016”.
- <sup>800</sup> USDA (2015), “Singapore – Agricultural Biotechnology Annual”, p.3.
- <sup>801</sup> Ibid.
- <sup>802</sup> Agri-Food & Veterinary Authority of Singapore, Agrotechnology Parks Map, (Accessed June 2016): <http://www.ava.gov.sg/explore-by-sections/farms/land-farms/farming-in-singapore/agrotechnology-parks-map>
- <sup>803</sup> Agriculture Extension and Advisory Service Worldwide, Singapore – Public Sector Advisory Services, (Accessed June 2016), <http://www.worldwide-extension.org/asia/singapore>
- <sup>804</sup> Seed World (2015), “DuPont Establishes New Headquarters in Singapore”, 10/2/2015, <http://seedworld.com/duPont-establishes-new-headquarters-in-singapore/>
- <sup>805</sup> DuPont Singapore (2009), “DuPont Singapore Factsheet”, pp. 1-2.
- <sup>806</sup> Singapore Environment Council (2007), “Elements”, Issue 2 of 2007, p. 3.
- <sup>807</sup> EDB, “Clean Energy, In Brief”, (Accessed June 2016), <https://www.edb.gov.sg/content/edb/en/industries/industries/clean-energy.html>
- <sup>808</sup> Ibid.
- <sup>809</sup> Eco-Business (2014), “Singapore’s First Biodiesel-powered Luxury Fleet to be powered by Cooking Oil”, 1/21/2014.
- <sup>810</sup> Future Ready Singapore (2016), “But Does it Smell like Fries? Why this Mall Contains a Tiny Biofuel Refinery”, 2/25/2016, <https://www.futurereadysingapore.com/2016/but-does-it-smell-like-fries-why-this-mall-contains-a-tiny-biofuel-refinery.html>
- <sup>811</sup> Energy Trends Insider (2014), “Global Biofuels Status Update”, 8/28/2014, (Accessed June 2016), <http://www.energytrendsinsider.com/2014/08/28/global-biofuels-status-update/>
- <sup>812</sup> Times Higher Education World University Rankings 2015-2016.
- <sup>813</sup> World Bank, Data bank, Scientific and technical journal articles, IP.JRN.ARTC.SC.
- <sup>814</sup> World Bank databank.
- <sup>815</sup> OECD (2016), p. 21.
- <sup>816</sup> Ibid.
- <sup>817</sup> Ibid. p. 32.
- <sup>818</sup> OECD (2013), “Singapore: Innovation Profile”, *Innovation in Southeast Asia*, OECD Publishing, p. 230.
- <sup>819</sup> A\*STAR website (accessed June 2016), <http://www.a-star.edu.sg/About-A-STAR.aspx>
- <sup>820</sup> EDB (2014).
- <sup>821</sup> Ibid.
- <sup>822</sup> Clinicaltrials.gov, (Accessed October 2015): <https://clinicaltrials.gov/ct2/search/map/click?map.x=556&map.y=215>
- <sup>823</sup> Ibid.
- <sup>824</sup> OECDSTAT, Patents by technology, Triadic Patent families, Inventor(s)'s country(ies) of residence, Priority date, Biotechnology
- <sup>825</sup> A Groh et al (2015), “Venture Capital & Private Equity Country Attractiveness Index 2015, IESE and EMLYON.
- <sup>826</sup> Cantab IP, IP Guides, Patent Term Extensions for Pharma Patents in Singapore, (Accessed May 2016), <http://www.cantab-ip.com/Life-Sciences/Pharmaceutical-Patent-Term-Extensions.html>

- <sup>827</sup> Orphanet, About orphan drugs, Orphan drugs in Singapore, (Accessed June 2016), [http://www.orpha.net/consor/cgi-bin/Education\\_AboutOrphanDrugs.php?lng=EN&stapage=ST\\_EDUCATION\\_EDUCATION\\_ABOUTORPHANDRUGS\\_SIN](http://www.orpha.net/consor/cgi-bin/Education_AboutOrphanDrugs.php?lng=EN&stapage=ST_EDUCATION_EDUCATION_ABOUTORPHANDRUGS_SIN)
- <sup>828</sup> MF Schultz and D Lippoldt (2014), “Approaches to Protection of Undisclosed Information (Trade Secrets), Background Paper”, OECD, p. 31.
- <sup>829</sup> IPOS, What is plant varieties protection?, (Accessed June 2016), <http://www.ipos.gov.sg/AboutIP/TypesofIP/WhatIsIntellectualProperty/WhatIsplantvarietiesprotection.aspx>
- <sup>830</sup> Health Science Authority website (accessed November 2015), “Home, Health Products Regulation”, [http://www.hsa.gov.sg/content/hsa/en/Health\\_Products\\_Regulation.html](http://www.hsa.gov.sg/content/hsa/en/Health_Products_Regulation.html)
- <sup>831</sup> A. Gross (2014), “Singapore’s Pharmaceutical Industry 2014 Update”, PharmaForum, 02/13/2014, <http://www.pharmaphorum.com/articles/singapores-pharmaceutical-industry-2014-update>
- <sup>832</sup> LG Baird et al. (2014), “Accelerated Access to Innovative Medicines for Patients in Need”, 12/2014
- <sup>833</sup> Ibid.
- <sup>834</sup> USDA (2013), “Agricultural Biotechnology Annual, Singapore”, July 17 2013.
- <sup>835</sup> EDB (2014).
- <sup>836</sup> WIPO (2015), “PCT Yearly Review 2014, p.40.
- <sup>837</sup> OECD (2013iii), p. 230.
- <sup>838</sup> IPI, “Highlights, Success Stories” (accessed June 2016), <https://www.ipi-singapore.org/success-stories?page=1>
- <sup>839</sup> Nezu et al, (2007), p. 11.
- <sup>840</sup> National Research Foundation, Translating Research, Engaging Innovation, Delivering Solutions” (accessed May 2016), <http://www.nrf.gov.sg/rie2020/growing-a-vibrant-national-innovation-system>
- <sup>841</sup> E&Y (2015), Worldwide R&D incentives Reference Guide2014–15”, p.198; KPMG (2016).
- <sup>842</sup> KPMG (2016).
- <sup>843</sup> WJP (2014), p. 45.
- <sup>844</sup> World Bank (2015), “South Africa data”, <http://data.worldbank.org/country/south-africa>
- <sup>845</sup> World Bank (2015), “South Africa overview” <http://www.worldbank.org/en/country/southafrica/overview>
- <sup>846</sup> Ibid; IMF (2015), “World Economic Outlook: Adjusting to Lower Commodity Prices”, 10/2015, p.2,
- <sup>847</sup> Klaus Schaub/World Economic Forum (2015), “The Global Competitiveness Report 2015–2016”, 09/2015
- <sup>848</sup> South African Department of Science and Technology, (2008), “Ten-Year Innovation Plan”.
- <sup>849</sup> The Technology Innovation Agency, (2015), “About Us”, (Accessed May 2016), <http://www.tia.org.za/about-us>
- <sup>850</sup> Ibid.
- <sup>851</sup> Ibid., “Funding Application General Guidelines”, pages 6-7.
- <sup>852</sup> Ibid., “Tshwane Animal Health Innovation Cluster Initiative”.
- <sup>853</sup> Ibid., “Our Projects”.
- <sup>854</sup> Ministry of Science and Technology (2014), “The Bio-Economy Strategy”, pp. 3-4.
- <sup>855</sup> Ibid. pp. 23-4.
- <sup>856</sup> Ibid. p. 38.
- <sup>857</sup> Ibid. p. 21.
- <sup>858</sup> I Parker et al (2001), “A National Biotechnology Strategy For South Africa, June 2001”, p. 62.
- <sup>859</sup> S. Al-Badr (2009), “Small But Tenacious: South Africa’s Health Biotech Sector”, *Nature Biotechnology*, volume 27, number 5, May 2009.
- <sup>860</sup> eGoLiBio, About Us, (Accessed May 2016), <http://www.egolibio.co.za/aboutus.htm>
- <sup>861</sup> Ibid.
- <sup>862</sup> Boitumelo Semete-Makotlela/SABC (2015), “SA Biotechnology Industry Growing But Can Still Do Better”, 8/23/2015, <http://www.sabc.co.za/news/a/411dce80499587adbbf2bba84320b537/SA-biotechnology-industry-growing-but-can-still-do-better>
- <sup>863</sup> OECD Key Biotechnology Indicators, Number of firms active in biotechnology, 2013 or latest available year
- <sup>864</sup> OECDStat, Biotechnology R&D intensity in the business sector, 2011 or latest available year, Biotechnology R&D in the business enterprise sector as a percentage of industry value added.
- <sup>865</sup> Ibid.
- <sup>866</sup> IPAP 2017/18 -2018/19, p.117.
- <sup>867</sup> Sanofi South Africa, Manufacturing Facility, (Accessed May 2016), <http://www.sanofi.co.za/!za/en/layout.jsp?scat=2235DDE7-03E4-4F71-9FEF-ACFC65034618>
- <sup>868</sup> Ibid.
- <sup>869</sup> 2014 Bio-economy Strategy, p. 4.
- <sup>870</sup> Deloitte (2015), p. 2.
- <sup>871</sup> Ibid, p. 30.
- <sup>872</sup> IPAP 2016/17 – 2018/19, p.119.
- <sup>873</sup> Iain M. Cockburn, Jean O. Lanjouw, Mark Schankerman (2014) “Patents and the Global Diffusion of New Drugs”, NBER Working Paper No. 20492, Table A2, p. 43.
- <sup>874</sup> Pugatch Consilium (2016), “Measuring The Global Biomedical Pulse The Biopharmaceutical Investment & Competitiveness (Bci) Survey – 2016”.
- <sup>875</sup> ISAA (2015), p. 2.

- <sup>876</sup> Ibid., p.7.
- <sup>877</sup> Reuters (2016), “South Africa to Ease Some GM Crop rules to Avert Food Crisis”, 2/23/2016, <http://www.reuters.com/article/us-safrica-maize-gmo-idUSKCN0VW0VS>
- <sup>878</sup> ISAA (2015).
- <sup>879</sup> Ibid.
- <sup>880</sup> Dana Sanchez/AFK Insider (2015), “South Africa Rejects Commercial Production Of GMO Potatoes”, 9/25/2015, <https://www.geneticliteracyproject.org/2015/09/25/south-africa-rejects-commercial-production-of-gmo-potatoes/>
- <sup>881</sup> USDA (2015), “Biotechnology in South Africa Annual”, 7/14/2015, p. 2.
- <sup>882</sup> Ibid.
- <sup>883</sup> Ibid.
- <sup>884</sup> Ministry of Science, (2014), p. 32.
- <sup>885</sup> BP (2015), p. 39.
- <sup>886</sup> South African Government (2014), “Position Paper on the South African Biofuels Regulatory Framework: Draft”.
- <sup>887</sup> A Gilder & M Mamkeli (2014), “Biofuels in South Africa”, ENSafrica.
- <sup>888</sup> Ibid.
- <sup>889</sup> Johan Krige (2015), “Biofuels Regulation in South Africa”, 12/19/2015, <http://www.slideshare.net/JohannKrige/biofuels-regulation-in-south-africa>
- <sup>890</sup> Engineer News (2015), “Doe Goes To Ground Over Mandatory Blending Of Biofuels Deadline”, 3/16/2015, <http://www.engineeringnews.co.za/article/doe-goes-to-ground-over-mandatory-blending-of-biofuels-policy-deadline-2015-03-06>
- <sup>891</sup> Reuters (2015), “Cheaper Oil Forces South Africa to Rework Biofuels Subsidy”, 8/11/2015, <http://af.reuters.com/article/topNews/idAFKCN0QG0RJ20150811>
- <sup>892</sup> Times Higher Education World University Rankings 2015-2016.
- <sup>893</sup> Ibid. BRICS and emerging economies rankings 2015.
- <sup>894</sup> World Bank, Data bank, Scientific and technical journal articles, IP.JRN.ARTC.SC.
- <sup>895</sup> OECD (2015), “Science, Technology and Industry Scoreboard 2015”, 2.6.1 The quantity and quality of scientific production, 2003-12, OECDstat.
- <sup>896</sup> World Bank databank.
- <sup>897</sup> OECD Science & Technology Indicators, 2015 Issue 2, p. 21.
- <sup>898</sup> Ibid. p. 32.
- <sup>899</sup> Naledi Pandor (2016), “Global Boost Needed To Double Science Research“, 5/10/2016, <http://www.bdlive.co.za/opinion/2016/05/10/global-boost-needed-to-double-science-research>
- <sup>900</sup> Ibid.
- <sup>901</sup> Science and Technology Department (2014), National Survey of R&D Development, Main Analysis Report 2012/2013”, 11/2014p. 23, [http://www.dst.gov.za/images/pdfs/RD\\_Survey\\_Main\\_Analysis\\_Report\\_2012\\_2013.pdf](http://www.dst.gov.za/images/pdfs/RD_Survey_Main_Analysis_Report_2012_2013.pdf)
- <sup>902</sup> Ibid, p.15.
- <sup>903</sup> NIH/clinicaltrials.gov
- <sup>904</sup> Ibid.
- <sup>905</sup> Ibid.
- <sup>906</sup> OECDSTAT, Patents by technology, Triadic Patent families, Inventor(s)'s country(ies) of residence, Priority date, Biotechnology.
- <sup>907</sup> A Groh et al (2015), “Venture Capital & Private Equity Country Attractiveness Index 2015”, IESE and EMLYON.
- <sup>908</sup> Department of Trade and Industry, (2013), “Draft national Policy on Intellectual Property”.
- <sup>909</sup> Only one of the eight bills has been published for consultation in 07/2015, the Copyright bill, available at <http://www.gov.za/documents/copyright-amendment-bill-comments-invited-27-jul-2015-0000>
- <sup>910</sup> Kei Online (2016), “Keynote Address of Minister Rob Davies (South Africa) to WIPO International Conference on IP and Development”, 4/7/2016, <http://keionline.org/node/2456>
- <sup>911</sup> Lexology/ Fasken Martineau DuMoulin LLP (2016), “Meet SAHPRA - New Regulator of Medicines, Medical Devices and IVDs”, 2/29/2016, <http://www.lexology.com/library/detail.aspx?g=b47d21e3-0d2e-4137-b298-538f4b027ee7>
- <sup>912</sup> BD Live (2016), “Department Aims To Launch New Health Products Watchdog Next Year”, 1/22/2016, <http://www.bdlive.co.za/national/health/2016/01/22/department-aims-to-launch-new-health-products-watchdog-next-year>
- <sup>913</sup> BD Live (2016).
- <sup>914</sup> The Intellectual Property Rights from Publicly Financed Research and Development Act, South Africa Government Gazette, 12/22/2008.
- <sup>915</sup> Ibid. section 4(1).
- <sup>916</sup> WIPO (2014), “Patent Cooperation Treaty Yearly Review”, p. 25.
- <sup>917</sup> Ibid.
- <sup>918</sup> OECD (2014), “STI Outlook”, p. 421.



- <sup>919</sup> CSIR, Our Activities, (Accessed June 2016), <http://www.techtransfer.csir.co.za/our-services/>
- <sup>920</sup> CSIR, Instant Access Licensing: Fast and Easy Access to CSIR Technologies, (Accessed June 2016), <http://www.techtransfer.csir.co.za/csir-instant-access-licensing-fast-and-easy-access-to-csir-technologies/>
- <sup>921</sup> Department of Trade and Industry (2013), “National Industrial Participation Revised Guidelines 2013”, [https://www.thedti.gov.za/industrial\\_development/docs/nipp/Nip\\_Guidelines2013.pdf](https://www.thedti.gov.za/industrial_development/docs/nipp/Nip_Guidelines2013.pdf)
- <sup>922</sup> Ibid.
- <sup>923</sup> Department of Trade and Industry (2015), “IPAP 2015”, p. 50.
- <sup>924</sup> Deloitte (2015), “Global Survey of R&D Tax Incentives”, October 2015, p. 45.
- <sup>925</sup> South African Government, “Science and Technology kicks off Government-Industry Task Team on R&D Tax Incentive”, 11/30/2015, <http://www.gov.za/speeches/science-and-technology-kicks-government-industry-task-team-rd-tax-incentive-30-nov-2015-0000>
- <sup>926</sup> Ibid.
- <sup>927</sup> Ibid.
- <sup>928</sup> Text available at [https://www.thedti.gov.za/industrial\\_development/docs/SEZ\\_Act.pdf](https://www.thedti.gov.za/industrial_development/docs/SEZ_Act.pdf)
- <sup>929</sup> Department of Trade and Industry website (accessed September 2015), “Special Economic Zones”, [https://www.thedti.gov.za/industrial\\_development/sez.jsp](https://www.thedti.gov.za/industrial_development/sez.jsp)
- <sup>930</sup> South Africa Government Portal (2015), “Western Cape Economic Development and Tourism launches Health Tech Park”, 05/14/2015 <http://www.gov.za/speeches/r600m-health-tech-park-drive-sa%E2%80%99s-medical-innovation-14-may-2015-0000>
- <sup>931</sup> Regulations Relating to a Transparent Pricing System for Medicines and Scheduled Substances published in Government Gazette N. 28214 of 11/11/2005.
- <sup>932</sup> HIS (2015), “South Africa's DoH Asks Companies to Disclose Drug Prices in Other Countries, Caps Medicine Price Increase”, 06/03/2015, <https://www.ihs.com/country-industry-forecasting.html?ID=1065998855>
- <sup>933</sup> Regulation 10361 of 02/04/2015, point 3.2.2. Text available at <http://www.health.gov.za/index.php/single-exit-price-documents?download=836:2015-sepa-notice-and-guidelines>
- <sup>934</sup> BD Live (2015), “SA to Press Drug Firms to Lower Prices”, 02/2015, <http://www.bdlive.co.za/business/healthcare/2015/02/06/sa-to-press-drug-firms-to-lower-their-prices>
- <sup>935</sup> Text available at [http://www1.chr.up.ac.za/undp/domestic/docs/legislation\\_54.pdf](http://www1.chr.up.ac.za/undp/domestic/docs/legislation_54.pdf)
- <sup>936</sup> Health24 (2013), “New Dispensing Fees To Boost Generic Sales ‘”, 10/08/2013, <http://www.health24.com/Medical/Meds-and-you/News/New-dispensing-fees-to-boost-generic-sales-20131008>
- <sup>937</sup> World Bank (2014).
- <sup>938</sup> World Bank, Data bank, GDP per capita (current US\$), Switzerland.
- <sup>939</sup> World Economic Forum (2014), p. 13.
- <sup>940</sup> SEFRI (2016), “Research And Innovation In Switzerland In 2016”, 4/26/2016, <http://www.sbf.admin.ch/themen/01367/02847/index.html?lang=fr>
- <sup>941</sup> Secrétariat d’Etat à la formation, à la recherche et à l’innovation, SEFRI (Accessed May 2016), <http://www.sbf.admin.ch/org/01644/index.html?lang=fr>
- <sup>942</sup> Secreatariat d’Etat à l’Economie SECO (accessed May 2016), <https://www.secolive.admin.ch/themen/00374/00459/04076/index.html?lang=fr>
- <sup>943</sup> Swiss Biotech National Cluster (2016), “Switzerland Biotech Report 2016”, p.7, [http://www.swissbiotech.org/sites/swissbiotech.org/files/webmasterfiles/swissbiotechreport/sbr\\_2016\\_web.pdf](http://www.swissbiotech.org/sites/swissbiotech.org/files/webmasterfiles/swissbiotechreport/sbr_2016_web.pdf)
- <sup>944</sup> SNSF Annual Report 2014,p.12.
- <sup>945</sup> Ibid.
- <sup>946</sup> Federal Administration, Commission for Technology and Innovation, “Innosuisse” (accessed May 2016), <https://www.kti.admin.ch/kti/fr/home/ueber-uns/Innosuisse.html>
- <sup>947</sup> Swiss Biotech (2016).
- <sup>948</sup> Swiss Biotech (2016), p.18.
- <sup>949</sup> EY (2015), “Swiss Biotech Report 2015”, March 2015, pp.28-30.
- <sup>950</sup> Ibid.
- <sup>951</sup> Ibid.
- <sup>952</sup> PwC (2016), “The Global Innovation 1000: Top 20 R&D Spenders 2005-2015”
- <sup>953</sup> Interpharma (2015), “Swiss Healthcare and Pharmaceutical Market”, p. 79.
- <sup>954</sup> Ibid.
- <sup>955</sup> Ibid, p.72.
- <sup>956</sup> Ibid., p.63.
- <sup>957</sup> Ibid., p.66.
- <sup>958</sup> Ibid.,p.77.
- <sup>959</sup> European Biotechnology (2015), “Swiss Biotech Reveals in Good Mood”, 4/16/2015, <http://www.european-biotechnology-news.com/news/news/2015-02/swiss-biotech-day.html>
- <sup>960</sup> Iain M. Cockburn, Jean O. Lanjouw, Mark Schankerman (2014) “Patents and the Global Diffusion of New Drugs”, NBER Working Paper No. 20492, Table A2, p. 43.
- <sup>961</sup> Pugatch Consilium (2016) Measuring The Global Biomedical Pulse The Biopharmaceutical Investment & Competitiveness (Bci) Survey – 2016.

- <sup>962</sup> GMO-free Europe, Switzerland Updates + Overviews, <http://www.gmo-free-regions.org/gmo-free-regions/switzerland.html>
- <sup>963</sup> Federal Office for the Environment (FOEN), “Experimental Release of Genetically Modified Organisms (GMOs)”, (Accessed June 2016), <http://www.bafu.admin.ch/biotechnologie/01756/08902/index.html?lang=en>
- <sup>964</sup> Swiss Expert Committee for Biosafety, “Field Trials with Genetically Modified Plants” (accessed May 2016), <http://www.efbs.admin.ch/en/topics/experimental-releases/genetically-modified-plants/>
- <sup>965</sup> Agroscope, “Site for Field Trials of Genetically Modified Plants”, (Accessed May 2016), <http://www.agroscope.admin.ch/biosicherheit/06948/index.html?lang=en>
- <sup>966</sup> Agroscope (2015), “Annual Report 2014”, p.15, 6/5/2015.
- <sup>967</sup> Agroscope (2016), “Annual Report 2015”, p. 10, 5/26/2016.
- <sup>968</sup> Syngenta, Crops & Innovation, R&D Overview, (Accessed May 2016), <http://www.syngenta.com/global/corporate/en/products-and-innovation/research-development/Pages/rd-overview.aspx>
- <sup>969</sup> Swiss Biotech (2014), “Swiss Biotech Report 2014”, p. 15.
- <sup>970</sup> Ibid.
- <sup>971</sup> DuPont, Global R&D Centers, Meyrin, Switzerland, (Accessed May 2016), <http://www.dupont.com/corporate-functions/our-approach/science/dupont-research-development-centers-worldwide/meyrin-switzerland-the-european-technical-center.html>
- <sup>972</sup> Ibid. <http://www.dupont.com/corporate-functions/our-approach/science/innovation-centers/innovation-center-geneva.html>
- <sup>973</sup> SERI (2016), “Science and Innovation Report”, p.167.
- <sup>974</sup> Times Higher Education World University Rankings 2015-2016.
- <sup>975</sup> World Bank, Data bank, Scientific and technical journal articles, IP.JRN.ARTC.SC.
- <sup>976</sup> OECD (2015), “Science, Technology and Industry Scoreboard 2015”, 2.6.1 The quantity and quality of scientific production, 2003-12, OECDstat.
- <sup>977</sup> World Bank databank.
- <sup>978</sup> OECD (2016) p. 21.
- <sup>979</sup> Ibid.
- <sup>980</sup> Ibid. p. 32.
- <sup>981</sup> SERI (2016), “Research and Innovation in Switzerland 2016”, p.41.
- <sup>982</sup> Ibid.
- <sup>983</sup> Ibid.
- <sup>984</sup> Ibid.
- <sup>985</sup> NIH/Clinicaltrials.gov
- <sup>986</sup> Ibid.
- <sup>987</sup> OECDSTAT, Patents by technology, Triadic Patent families, Inventor(s)'s country(ies) of residence, Priority date, Biotechnology.
- <sup>988</sup> A Groh et al (2015), “Venture Capital & Private Equity Country Attractiveness Index 2015”, IESE and EMLYON.
- <sup>989</sup> Swiss Federal Institute of Intellectual Property, Supplementary Protection Certificate (SPC).
- <sup>990</sup> Swiss Federal Office of Public Health and WHO, (2011), “Switzerland Pharmaceutical Country Profile”, September 2011, pp. 13-19.
- <sup>991</sup> *Swissinfo* (2012) “Scientists’ Findings Don’t Satisfy Politicians”, (Accessed June 2016), [http://www.swissinfo.ch/eng/science\\_technology/Scientists\\_findings\\_don\\_t\\_satisfy\\_politicians.html?cid=33604154](http://www.swissinfo.ch/eng/science_technology/Scientists_findings_don_t_satisfy_politicians.html?cid=33604154)
- <sup>992</sup> GMWatch.org (2015), “Switzerland will Extend Moratorium on GM Crop Cultivation”, 12/22/2015, <http://www.gmwatch.org/news/latest-news/16615-switzerland-will-extend-moratorium-on-gm-crop-cultivation>
- <sup>993</sup> Natural Society (2016), “Switzerland Fed Council Extends GM Moratorium Until 2021”, 1/6/2016, <http://naturalsociety.com/switzerland-fed-council-extends-gm-moratorium-until-2021/>
- <sup>994</sup> Ibid.
- <sup>995</sup> SERI (2015), “Higher Education and Research in Switzerland”, p.26.
- <sup>996</sup> swiTT, About swiTT, Mission: [http://www.switt.ch/about\\_switt/mission/](http://www.switt.ch/about_switt/mission/)
- <sup>997</sup> swiTT (2013), “swiTTreport 2013”, p. 5.
- <sup>998</sup> Swiss Biotech Report (2016), p.15.
- <sup>999</sup> Ibid.
- <sup>1000</sup> WIPO (2015), “Patent Cooperation Treaty Yearly Review 2015”, p.43.
- <sup>1001</sup> Pugatch Analysis based on WIPO PCT Data 2015.
- <sup>1002</sup> EY (2015), “Worldwide R&D incentives Reference Guide 2014–15”, p.239.
- <sup>1003</sup> SERI (2016). Innovation Report, p.174.
- <sup>1004</sup> RSM (2016), “Third corporate tax reform (CTR III)”, 1/14/2016, <http://www.rsm.global/switzerland/news/corporate-tax-reform-iii>
- <sup>1005</sup> Swiss Customs Administration, Fuels from renewable feedstocks, (Accessed May 2016), [http://www.ezv.admin.ch/zollinfo\\_firmen/04020/04256/04263/04530/index.html?lang=en](http://www.ezv.admin.ch/zollinfo_firmen/04020/04256/04263/04530/index.html?lang=en)

- <sup>1006</sup> World Bank Data (2015).
- <sup>1007</sup> Klaus Schwab/World Economic Forum (2015), “The Global Competitiveness Report 2015-2016”, 09/2015.
- <sup>1008</sup> The Scientific and Technological Research Council of Turkey, Who we are? (Accessed June 2016), <http://www.tubitak.gov.tr/en/about-us/content-who-we-are>
- <sup>1009</sup> Ibid. National STI strategy 2011-2016.
- <sup>1010</sup> OECD (2012), “STI Outlook: Turkey”.
- <sup>1011</sup> Ibid.
- <sup>1012</sup> Invest in Turkey, “Turkey Special Investment Zones”, (Accessed May 2016), <http://www.invest.gov.tr/en-US/investmentguide/investorsguide/Pages/SpecialInvestmentZones.aspx>
- <sup>1013</sup> Today’s Zaman (2014), “R&D Has A Way To Go In Turkey”, 26/11/2014,
- <sup>1014</sup> D. Cetindamar & A. Rickne (2013). “Turkish Biotech”, from 35th DRUID Celebration Conference
- <sup>1015</sup> Invest in Turkey, “Turkey Special Investment Zones”, (Accessed May 2016), <http://www.invest.gov.tr/en-US/investmentguide/investorsguide/Pages/SpecialInvestmentZones.aspx>
- <sup>1016</sup> Ibid.
- <sup>1017</sup> Regfollower (2016), “Turkey: R&D Reform Package Enters into Force”, 2/26/2016, <https://regfollower.com/2016/02/26/turkey-rd-reform-package-enters-into-force/>
- <sup>1018</sup> Invest In Turkey (2016), “New R&D Reform Package to Boost Innovation”, 2/22/2016, <http://www.invest.gov.tr/en-US/infocenter/news/Pages/220216-turkey-new-r-d-reform-package-launched.aspx>
- <sup>1019</sup> Daily Sabah Business (2016), “New Reform Package Lowers Cost in R&D for Turkish Companies”, 1/14/2016, <http://www.dailysabah.com/money/2016/01/15/new-reform-package-lowers-cost-in-rd-for-turkish-companies>
- <sup>1020</sup> Anatolou Agency (2014), “Action Plan on the Structural Transformation of Health Industries”, p.1.
- <sup>1021</sup> Ö. Atılgan Karakulak and Z. Koray (2015), “Turkey, a Rising Star in the Pharmaceutical Industry”, 01/03/2015, <http://gun.av.tr/turkey-rising-star-pharmaceutical-industry/>
- <sup>1022</sup> Text available in Turkish at <http://www.resmigazete.gov.tr/eskiler/2015/08/20150809-16-1.pdf>
- <sup>1023</sup> P.22, Art.46. Text available at <http://www.tbb.gov.tr/download.php?dosya=storage/catalogs/0053903001451150339.pdf&dosyaAdi=hukumet-eylem-planinda-tbbye-gorev>.
- <sup>1024</sup> PhRMA (2016).
- <sup>1025</sup> PhRMA (2014), “Special 301 Submission 2014”. p. 38.
- <sup>1026</sup> Ibid.
- <sup>1027</sup> Ibid.
- <sup>1028</sup> Iain M. Cockburn, Jean O. Lanjouw, Mark Schankerman (2014) “Patents and the Global Diffusion of New Drugs”, NBER Working Paper No. 20492, Table A2, p. 43.
- <sup>1029</sup> Pugatch Consilium (2016), “Measuring The Global Biomedical Pulse The Biopharmaceutical Investment & Competitiveness (Bci) Survey – 2016”.
- <sup>1030</sup> USDA, (2014), “Turkey Agricultural Biotechnology Annual”, *GAIN report*, 7/18/2014.
- <sup>1031</sup> Ibid.
- <sup>1032</sup> USDA (2015), “2015 Biotechnology Annual”, *GAIN report*, 4/15/2015, p.1.
- <sup>1033</sup> EUROPABIO (2009), *Biotechnology Report, Turkey, Europabio And Venture Valuation*, 2009, p. 2.
- <sup>1034</sup> Pakmaya, About Us, Pakmaya Worldwide, (Accessed May 2016), <http://www.pakmaya.com.tr/en/Hakkimizda/Index/8>
- <sup>1035</sup> Ibid.
- <sup>1036</sup> BIOMER, “About Us”, (Accessed May 2016), <http://biyomer.iyte.edu.tr/en/hakkimizda/>
- <sup>1037</sup> G Bölük & A Koc (2013), “The Implications of Biofuel Policy in Turkey”, *International Journal of Energy Economics and Policy*, Vol. 3, Special Issue, 2013, pp.14-22.
- <sup>1038</sup> BP (2015), p. 39.
- <sup>1039</sup> Alex Usher (2015), “The Times Higher Education Rankings and the Mysterious Rise of Asia”, Winter 2015, *International Higher Education*, N.79, <https://ejournals.bc.edu/ojs/index.php/ihe/article/viewFile/5842/5206>
- <sup>1040</sup> World Bank, Data bank, Scientific and technical journal articles, IP.JRN.ARTC.SC.
- <sup>1041</sup> OECD (2015), “Science, Technology and Industry Scoreboard 2015”, 2.6.1; The quantity and quality of scientific production, 2003-12, OECDstat.
- <sup>1042</sup> World Bank databank.
- <sup>1043</sup> Ibid., p. 21.
- <sup>1044</sup> Ibid. p. 32.
- <sup>1045</sup> Istanbul Health Industry Cluster, “Health Industry joining Forces in Istanbul” (Accessed May 2016), [https://inovita.org/uploads/1404998946\\_ISEK\\_BROCHURE.pdf](https://inovita.org/uploads/1404998946_ISEK_BROCHURE.pdf)
- <sup>1046</sup> Cluster Izmir News (2015), “Turkey’s First Biomedicine and Genome Center is Opened”, 9/16/2015, <http://www.clusterizmir.org/#!Turkeys-First-Biomedicine-and-Genome-Center-is-Opened/c1x7t/55f958c10cf25bc37f00bfe2>
- <sup>1047</sup> NIH/Clinicaltrials.gov
- <sup>1048</sup> Ibid.
- <sup>1049</sup> Ibid.

- <sup>1050</sup> OECDSTAT, Patents by technology, Triadic Patent families, Inventor(s)'s country(ies) of residence, Priority date, Biotechnology.
- <sup>1051</sup> A Groh et al (2015), "Venture Capital & Private Equity Country Attractiveness Index 2015", IESE and EMLYON.
- <sup>1052</sup> PhRMA (2015), p. 27-8.
- <sup>1053</sup> The text was disclosed by the Turkish Patent Institute on 2/24/2016 and is available at <http://www.tpe.gov.tr/TurkPatentEnstitusu/allAnouncement/announcementDetail?newsId=510>
- <sup>1054</sup> FICPI (2016), "Draft Intellectual Property Law in Turkey", 5/3/2016, <http://www.ficpi.org/news/draft-intellectual-property-law-in-turkey/>
- <sup>1055</sup> Ilbars, H. (2013), "Clinical trials in Turkey", *Turkish Journal of Haematology: Official Journal of Turkish Society of Haematology*, 30(2), pp. 111-114.
- <sup>1056</sup> Phrma.Focus.Report.Net (2012), "Turkey: East, West and Profits!", October 2012, S7; PhRMA (2016), p. 80.
- <sup>1057</sup> PhRMA (2016), p. 80.
- <sup>1058</sup> USDA (2014), "Agricultural biotechnology annual – Turkey".
- <sup>1059</sup> Ibid.
- <sup>1060</sup> Ibid.
- <sup>1061</sup> Ibid.
- <sup>1062</sup> Y Hamzaoglu & O Hiziroglu (2010), "The Ownership Issues For Patentable Inventions Resulting From Publicly Funded Research In Turkey", *les Nouvelles*, December 2010.
- <sup>1063</sup> Decree Law No 551, article 41.
- <sup>1064</sup> B Rooney (2012), "Seeds Are There If Turkey Is Ready To Take Big Risks", *Wall Street Journal*, 10/17/2012.
- <sup>1065</sup> Technology transfer accelerator turkey (TTA), (Accessed May 2016), [http://www.eif.org/what\\_we\\_do/resources/ta/index.htm](http://www.eif.org/what_we_do/resources/ta/index.htm)
- <sup>1066</sup> European Investment Fund, "TTA Turkey Information Session", (Accessed May 2016), [http://www.eif.org/what\\_we\\_do/resources/ta/ta-turkey-info-session\\_05082014.pdf](http://www.eif.org/what_we_do/resources/ta/ta-turkey-info-session_05082014.pdf)
- <sup>1067</sup> The Scientific and Technological Research Council of Turkey, (Accessed May 2016), <http://www.tubitak.gov.tr/en/news/tubitak-aids-10-universities-in-opening-technology-transfer-offices>
- <sup>1068</sup> Ibid.
- <sup>1069</sup> Deloitte (2015), p. 44.
- <sup>1070</sup> Consultist (2014), "A Guide to Turkey's Investment Incentive System", 8/18/2014, <http://consultist.eu/a-guide-to-turkeys-investment-incentive-system/#Strategic>
- <sup>1071</sup> ISPAT/Deloitte (2014), "The Pharmaceutical Industry in Turkey", p.63, 01/2014, <http://www.invest.gov.tr/en-US/infocenter/publications/Documents/PHARMACEUTICAL.INDUSTRY.pdf>
- <sup>1072</sup> IEIS website, "Biotechnologic and Biogeneric Pharmaceuticals".
- <sup>1073</sup> PhRMA (2014), p. 38.
- <sup>1074</sup> M. Arseven (2012), "Pharmaceutical Regulation Under Turkish Law", 08/28/2012, [http://www.morogluarseven.com/news/pharmaceutical-regulations-under-turkish-law?utm\\_source=Mondaq&utm\\_medium=syndication&utm\\_campaign=View-Original](http://www.morogluarseven.com/news/pharmaceutical-regulations-under-turkish-law?utm_source=Mondaq&utm_medium=syndication&utm_campaign=View-Original); PhRMA "Special 301 Submission 2015", p.30.
- <sup>1075</sup> PMLive (2015), "Turkey: A Growing Pharma Market with Huge Potential", 01/2015, [http://www.pmlive.com/pharma\\_intelligence/turkey\\_a\\_growing\\_pharma\\_market\\_with\\_huge\\_potential\\_624153](http://www.pmlive.com/pharma_intelligence/turkey_a_growing_pharma_market_with_huge_potential_624153)
- <sup>1076</sup> Decree on Pricing of Medicinal Products for Human Use, 07/10/2015, Official Gazette N. 29412
- <sup>1077</sup> PharmAsia News (2015), "Turkey Drug Prices To Rise 4% As Government Settles Euro Issue", 07/15/2015 <https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/7/14/turkey-drug-prices-to-rise-4-as-govt-settles-euro-issue>
- <sup>1078</sup> World Justice Project, (2015).
- <sup>1079</sup> World Bank (2013).
- <sup>1080</sup> World Bank, Data bank, GDP per capita (current US\$), Mexico.
- <sup>1081</sup> World Economic Forum (2014), p. 13.
- <sup>1082</sup> W. Straw (2009), "British Innovation Policy", *Science Progress*, January 2009.
- <sup>1083</sup> Department for Business Innovation and Skills, About Us, (Accessed May 2016), <https://www.gov.uk/government/organisations/department-for-business-innovation-skills/about>
- <sup>1084</sup> The Department for Business, Innovation and Skills (BIS), "Blueprint for Technology", November 2010.
- <sup>1085</sup> IPO (2016), "Making Life Better By Supporting UK Creativity And Innovation: The Intellectual Property Office's Five Year Strategy 2015-2020", 1/21/2016, <https://www.gov.uk/government/publications/making-life-better-by-supporting-uk-creativity-and-innovation>
- <sup>1086</sup> Gov.uk (2016), "Government Vows To Make UK Best In Europe For Innovation And IP", 1/21/2016, <https://www.gov.uk/government/news/government-vows-to-make-uk-best-in-europe-for-innovation-and-ip>
- <sup>1087</sup> HM Government (2015), "Strengths and Opportunities 2014: The Landscape Of The Medical Technology, Medical Biotechnology, Pharmaceutical And Industrial Biotechnology Sectors In The UK", p.4, [https://www.gov.uk/government/uploads/system/uploads/attachment\\_data/file/427769/BIS-15-](https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/427769/BIS-15-)
- <sup>1088</sup> The Manufacturer, UK Manufacturing Statistics (Accessed May 2016): <http://www.themanufacturer.com/uk-manufacturing-statistics/>
- <sup>1089</sup> IPO (2016).

- <sup>1090</sup> The Manufacturer, UK Manufacturing Statistics.
- <sup>1091</sup> The Association of the British Pharmaceutical Industry, Research and Development, (Accessed May 2016): <http://www.abpi.org.uk/industry-info/knowledge-hub/randd/Pages/expenditure.aspx#6>
- <sup>1092</sup> Silicon Valley Bank (2015), “Trends in Healthcare Investments and Exits 2015”, p.8, [http://www.svb.com/uploadedFiles/Content/Blogs/Healthcare\\_Report/healthcare-report-2015.pdf](http://www.svb.com/uploadedFiles/Content/Blogs/Healthcare_Report/healthcare-report-2015.pdf)
- <sup>1093</sup> Ibid.
- <sup>1094</sup> IHS (2012), “Business Environment for Big Pharma Improving?”, IHS Blog 3/23/2012.
- <sup>1095</sup> Ibid.
- <sup>1096</sup> PharmaPhorum (2015), “AAR: ‘Conditional Yes’ Deals Will Speed Innovation Uptake”, 10/28/2015, <http://pharmaphorum.com/articles/aar-conditional-yes-deals-will-speed-innovation-uptake>
- <sup>1097</sup> Iain M. Cockburn, Jean O. Lanjouw, Mark Schankerman (2014) “Patents and the Global Diffusion of New Drugs”, NBER Working Paper No. 20492, Table A2, p. 43.
- <sup>1098</sup> Pugatch Consilium (2016), “Measuring The Global Biomedical Pulse The Biopharmaceutical Investment & Competitiveness (Bci) Survey – 2016”.
- <sup>1099</sup> USDA (2015), “UK Agricultural Biotechnology Annual 2015”, p.1, [http://gain.fas.usda.gov/Recent%20GAIN%20Publications/Agricultural%20Biotechnology%20Annual\\_London\\_United%20Kingdom\\_7-16-2015.pdf](http://gain.fas.usda.gov/Recent%20GAIN%20Publications/Agricultural%20Biotechnology%20Annual_London_United%20Kingdom_7-16-2015.pdf)
- <sup>1100</sup> Euractiv (2015), “Scotland to Issue Formal Ban on Genetically Modified Crops”, 8/10/2015, <http://www.euractiv.com/section/agriculture-food/news/scotland-to-issue-formal-ban-on-genetically-modified-crops/>
- <sup>1101</sup> Ibid.
- <sup>1102</sup> AgriTech Blog, About the Agri-Tech Strategy, (Accessed May 2016), <https://agritech.blog.gov.uk/about/>
- <sup>1103</sup> BBSRC, “Agri-Tech Catalyst” (accessed May 2016), <http://www.bbsrc.ac.uk/funding/filter/agri-tech-catalyst>
- <sup>1104</sup> Ibid.
- <sup>1105</sup> HM Government (2015), “Strengths and Opportunities 2014” p. 41.
- <sup>1106</sup> Department for Business, Enterprise & Regulatory Reform (2009), “IB 2025 Maximising UK Opportunities from Industrial Biotechnology in a Low Carbon Economy”, p. 7.
- <sup>1107</sup> Deloitte (2015), “Grants & Incentives Program Updates, The Latest Legislative Developments from Around the World”, February 2015.
- <sup>1108</sup> Ibid.
- <sup>1109</sup> BP (2015), p. 39.
- <sup>1110</sup> Ibid.
- <sup>1111</sup> The Telegraph (2016), “Motorists 'Face Higher Petrol Costs' To Hit EU Green Targets”, 1/15/2016, <http://www.telegraph.co.uk/news/uknews/road-and-rail-transport/12102804/Motorists-face-higher-petrol-costs-to-hit-EU-green-targets.html>
- <sup>1112</sup> Times Higher Education World University Rankings 2015–2016.
- <sup>1113</sup> Ibid. Life Sciences 2014–2015.
- <sup>1114</sup> World Bank, Data bank, Scientific and technical journal articles, IP.JRN.ARTC.SC.
- <sup>1115</sup> OECD (2015), “Science, Technology and Industry Scoreboard 2015”, 2.6.1, The quantity and quality of scientific production, 2003–12, OECDstat.
- <sup>1116</sup> World Bank databank.
- <sup>1117</sup> OECD (2015), p. 21.
- <sup>1118</sup> Ibid.
- <sup>1119</sup> Ibid. p. 30.
- <sup>1120</sup> NIH/Clinicaltrials.gov
- <sup>1121</sup> Ibid.
- <sup>1122</sup> Ibid.
- <sup>1123</sup> OECDSTAT, Patents by technology, Triadic Patent families, Inventor(s)'s country(ies) of residence, Priority date, Biotechnology.
- <sup>1124</sup> A Groh et al (2015), “Venture Capital & Private Equity Country Attractiveness Index 2015”, IESE and EMLYON.
- <sup>1125</sup> Telegraph (2016), “Brexit Could Slow Access To New Medicines And Delay Cure For Cancer” 5/23/2016, <http://www.telegraph.co.uk/news/2016/05/23/brexit-could-slow-access-to-new-medicines-and-delay-cure-for-cancer/>
- <sup>1126</sup> Isis Innovation (2015), “Annual Report 2015”, p.3.
- <sup>1127</sup> Imperial Innovations, Background to the Group, (Accessed May 2016), <http://www.imperialinnovations.co.uk/about/background/>
- <sup>1128</sup> Ibid.
- <sup>1129</sup> PWC, “Research and Development (R&D) Tax Credits” (Accessed May 2016), <http://www.pwc.co.uk/tax/issues/research-and-development-tax-credits.jhtml>
- <sup>1130</sup> Deloitte (2015), “2015 Global Survey of R&D Tax Incentives”, p. 86.
- <sup>1131</sup> Pharma Times (2015), “DH Consults Again On UK's Statutory Drug Pricing Scheme”, 9/11/2015, [http://www.pharmatimes.com/news/dh\\_consults\\_again\\_on\\_uks\\_statutory\\_drug\\_pricing\\_scheme\\_971879](http://www.pharmatimes.com/news/dh_consults_again_on_uks_statutory_drug_pricing_scheme_971879)

- <sup>1132</sup> Text available at [https://www.gov.uk/government/uploads/system/uploads/attachment\\_data/file/459219/stat\\_scheme\\_consultation\\_2015.pdf](https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/459219/stat_scheme_consultation_2015.pdf)
- <sup>1133</sup> ABPI (2015), “ABPI Statement On The Department Of Health Consultation On Changes To The Statutory Scheme”, 10/9/2015, <http://www.abpi.org.uk/media-centre/newsreleases/2015/Pages/100915.aspx>
- <sup>1134</sup> Gov.uk, “Accelerated Access Review: Interim Report”, p.15, October 2015, [https://www.gov.uk/government/uploads/system/uploads/attachment\\_data/file/471562/AAR\\_Interim\\_Report\\_acc.pdf](https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/471562/AAR_Interim_Report_acc.pdf)
- <sup>1135</sup> ABPI (2016), “ABPI Comment On New Cancer Drugs Fund Announcement”, 3/17/2016, <http://www.abpi.org.uk/media-centre/newsreleases/2016/Pages/170316.aspx>
- <sup>1136</sup> FierceBiotech (2016), “Charities And Pharma Decry 'Disgraceful' Changes To England's Cancer Drugs Fund”, 2/26/2016, <http://www.fiercebiotech.com/financials/charities-and-pharma-decry-disgraceful-changes-to-england-s-cancer-drugs-fund>
- <sup>1137</sup> Ibid.
- <sup>1138</sup> World Justice Project, (2015).
- <sup>1139</sup> World Bank (2014).
- <sup>1140</sup> World Bank, Data bank, GDP per capita (current US\$), United States.
- <sup>1141</sup> World Economic Forum (2015), p. 7.
- <sup>1142</sup> RD Atkinson/The Information Technology & Innovation Foundation (2014), “Understanding the U.S. National Innovation System”, June 2014, p. 5.
- <sup>1143</sup> White House (2015), “Fact Sheet: The White House Releases New Strategy for American Innovation, Announces Areas of Opportunity from Self-Driving Cars to Smart Cities”, 10/21/2015, <https://www.whitehouse.gov/the-press-office/2015/10/21/fact-sheet-white-house-releases-new-strategy-american-innovation>
- <sup>1144</sup> For a detailed breakdown of the strategic objectives and accompanying policies see Pugatch Consilium (2014), “Building the Bioeconomy Examining National Biotechnology Industry Development Strategies”, p. 41.
- <sup>1145</sup> An Innovation Strategy for America (2015), p.82.
- <sup>1146</sup> Ibid., p.98.
- <sup>1147</sup> Ibid.
- <sup>1148</sup> PhRMA (2015), “PhRMA Profile: Annual Membership Survey Results”, [http://www.phrma.org/sites/default/files/pdf/2015-phrma\\_profile\\_membership\\_results.pdf](http://www.phrma.org/sites/default/files/pdf/2015-phrma_profile_membership_results.pdf)
- <sup>1149</sup> Ross C. DeVol, Armen Bedroussian, Benjamin Yeo (2011), “The Global Biomedical Industry: Preserving U.S. Leadership”, p.10, September 2011, Milken Institute, <http://assets1b.milkeninstitute.org/assets/Publication/ResearchReport/PDF/CASMIFullReport.pdf>
- <sup>1150</sup> Massachusetts Biotechnology Council (2016), “Industry Snapshot”, p. 30, <http://files.massbio.org/file/2015-Industry-Snapshot-Updated.pdf>
- <sup>1151</sup> NIH, “About NIH” (Accessed May 2016), <http://www.nih.gov/about/budget.htm>
- <sup>1152</sup> Ibid.
- <sup>1153</sup> Science (2015), “Budget Agreement Boosts US Science”, 12/18/2015, <http://www.sciencemag.org/news/2015/12/updated-budget-agreement-boosts-us-science>
- <sup>1154</sup> J Loscalzo (2006) “The NIH Budget and the Future of Biomedical Research”, *New England Journal of Medicine*, 2006; 354: pp. 1665-1667.
- <sup>1155</sup> National Cancer Institute, “National Cancer Moonshot Initiative Research Areas” (Accessed May 2016), <http://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative/research-areas>
- <sup>1156</sup> White House (2016), “The President's Budget for Fiscal Year 2017”, <https://www.whitehouse.gov/omb/budget>
- <sup>1157</sup> PwC, (2015), “California Biomedical Industry 2015 Report”, p. 4.
- <sup>1158</sup> PhRMA (2016).
- <sup>1159</sup> PwC (2015), p.3.
- <sup>1160</sup> Ibid.
- <sup>1161</sup> Massachusetts Biotechnology Council (2016), pp. 4.8.
- <sup>1162</sup> Massachusetts Biotechnology Council website (accessed May 2016), <https://www.massbio.org/why-massachusetts/industrysnapshot>
- <sup>1163</sup> Massachusetts Biotechnology Council, “Contract Research & Contract Manufacturing in MA” (accessed May 2016), <https://www.massbio.org/why-massachusetts/supercluster/contract-research-and-manufacturing>
- <sup>1164</sup> Governor’s Office of Business and Economic Development, “Business Incentives” (accessed May 2016), <http://business.ca.gov/RelocateExpand/BusinessIncentives.aspx>; Massachusetts Biotechnology Council, “Massachusetts Incentives”, <https://www.massbio.org/why-massachusetts/incentives>
- <sup>1165</sup> Iain M. Cockburn, Jean O. Lanjouw, Mark Schankerman (2014) “Patents and the Global Diffusion of New Drugs”, NBER Working Paper No. 20492, Table A2, p. 43.
- <sup>1166</sup> Pugatch Consilium (2016), “Measuring The Global Biomedical Pulse The Biopharmaceutical Investment & Competitiveness (Bci) Survey – 2016”.
- <sup>1167</sup> ISSA (2015), p. 2.
- <sup>1168</sup> NBC news (2016), “Genetically Modified Crops Are Safe, Report Says”, 5/17/2016, <http://www.nbcnews.com/health/health-news/genetically-modified-crops-are-safe-report-says-n575436>

- <sup>1169</sup> S. Wyant (2014) “President Obama Provides Clear Endorsement Of Agricultural Biotechnology”, *Agri-Pulse*, 4/15/2014.
- <sup>1170</sup> Reuters (2016), “Senate Blocks Bill that Would Override State GMO Labeling Laws“, 3/16/2016, <http://www.reuters.com/article/us-usa-gmo-labeling-idUSKCN0WI2K2>
- <sup>1171</sup> Politico (2016), “Merkley Shoots For Mandatory GMO Labeling”, 3/2/2016, <http://www.politico.com/tipsheets/morning-agriculture/2016/03/merkley-shoots-for-mandatory-gmo-labeling-demands-divided-usda-officially-puts-cool-on-chopping-block-212996>
- <sup>1172</sup> Environmental Leader (2016), “What Does the Dow-DuPont Merger Mean for Biomaterials?”, 3/10/2016, <http://www.environmentalleader.com/2016/03/10/what-does-the-dow-dupont-merger-mean-for-biomaterials/>
- <sup>1173</sup> National Institute of Food and Agriculture, Grants – 1890 Institution Teaching, Research and Extension Capacity Building Grants (CBG) Program, (Accessed May 2016), <http://www.csrees.usda.gov/fo/1890capacity.cfm>
- <sup>1174</sup> NIFA/USDA (2016), “President’s FY2017 Budget to Invest \$700 Million In USDA’s Agriculture and Food Research Initiative”, 2/3/2016, <https://nifa.usda.gov/resource/president%E2%80%99s-fy2017-budget-invest-700-million-usda%E2%80%99s-agriculture-and-food-research>
- <sup>1175</sup> NIFA/USDA (2016).
- <sup>1176</sup> Golden, J.S., Handfield, R.B., Daystar, J. and, T.E. McConnell (2015). “An Economic Impact Analysis of the U.S. Biobased Products Industry: A Report to the Congress of the United States of America.”6/12/2015, [http://www.biopreferred.gov/BPRResources/files/EconomicReport\\_6\\_12\\_2015.pdf](http://www.biopreferred.gov/BPRResources/files/EconomicReport_6_12_2015.pdf)
- <sup>1177</sup> Ibid., p.9.
- <sup>1178</sup> UNCTAD (2014), p. 10.
- <sup>1179</sup> Food Business News (2015), “E.P.A. Final Rule On Biofuel Requirements Draws Both Qualified Praise And Flak”, 12/3/2015, [http://www.foodbusinessnews.net/articles/news\\_home/Regulatory\\_News/2015/12/EPA\\_final\\_rule\\_on\\_biofuel\\_req\\_u.aspx?ID={4556871F-C487-4251-BD41-F6D92053C197}&cck=1](http://www.foodbusinessnews.net/articles/news_home/Regulatory_News/2015/12/EPA_final_rule_on_biofuel_req_u.aspx?ID={4556871F-C487-4251-BD41-F6D92053C197}&cck=1)
- <sup>1180</sup> USDA (2015), “Fact Sheet: USDA Invests in Clean Energy Economy, Supporting U.S. Producers and Seeking to Double Number of Higher Blend Renewable Fuel Pumps Available to Consumers”, Release No. 0157.15, <http://www.usda.gov/wps/portal/usda/usdahome?contentid=2015/05/0157.xml>
- <sup>1181</sup> BP (2015), p. 39.
- <sup>1182</sup> Ibid.
- <sup>1183</sup> BTO (2015), “Multi-Year Program Plan”, March 2015, p.12.
- <sup>1184</sup> Office of Energy Efficiency & Renewable Energy, Research, Development, Demonstration, and Deployment, (Accessed May 2016), <http://www.energy.gov/eere/bioenergy/research-development-demonstration-and-deployment>
- <sup>1185</sup> Energy.gov (2016), “DOE Announces \$10 Million for Innovative Bioenergy Research and Development”, 5/16/2016, <http://energy.gov/eere/articles/doe-announces-10-million-innovative-bioenergy-research-and-development>
- <sup>1186</sup> ARPA-E, Frequently Asked Questions, (Accessed May 2016), <http://arpa-e.energy.gov/?q=faq>
- <sup>1187</sup> ARPA-E, Tech-To-Market (T2M), (Accessed May 2016), <http://arpa-e.energy.gov/?q=arpa-e-site-page/tech-market-t2m>
- <sup>1188</sup> USDA, “Biomass Research and Development Initiative”, (accessed May 2016), <https://nifa.usda.gov/funding-opportunity/biomass-research-and-development-initiative-brdi>
- <sup>1189</sup> Genomic Science Program, Planet Feedstock Genomics for Bioenergy, (Accessed May 2016), <http://genomicscience.energy.gov/research/DOEUSDA/>
- <sup>1190</sup> Ibid. 2015 Awards.
- <sup>1191</sup> Times Higher Education World University Rankings 2015-2016.
- <sup>1192</sup> Ibid. Life Sciences.
- <sup>1193</sup> World Bank, Data bank, Scientific and technical journal articles, IP.JRN.ARTC.SC.
- <sup>1194</sup> OECD (2015), “Science, Technology and Industry Scoreboard 2015”, 2.6.1 The quantity and quality of scientific production, 2003-12, OECDstat
- <sup>1195</sup> World Bank databank.
- <sup>1196</sup> OECD (2015), p. 21.
- <sup>1197</sup> Ibid.
- <sup>1198</sup> Ibid. p. 32.
- <sup>1199</sup> NIH/clinicaltrials.gov
- <sup>1200</sup> Ibid.
- <sup>1201</sup> Ibid.
- <sup>1202</sup> OECDSTAT, Patents by technology, Triadic Patent families, Inventor(s)'s country(ies) of residence, Priority date, Biotechnology.
- <sup>1203</sup> A Groh et al (2015), “Venture Capital & Private Equity Country Attractiveness Index 2015”, IESE and EMLYON.
- <sup>1204</sup> M Pugatch, (2004), “ICTSD-UNCTAID Dialogue on Ensuring Policy Options for Affordable Access to Essential Medicines”.
- <sup>1205</sup> BIO (2011), “BIO Praises Final Passage of Patent Reform Legislation”, 9/8/2011.

- <sup>1206</sup> See: BIO (2013), “Myriad Supreme Court Decision: BIO’s Statement”, 6/13/2013 and E. Barraclough (2013), “What Myriad means for biotech”, *WIPO Magazine*, August 2013.
- <sup>1207</sup> See: The Economist (2012), “Prometheus Unsound”, 3/24/2012, and BIO (2012), “Mayo v. Prometheus: BIO Statement on Supreme Court Decision”, 3/20/2012.
- <sup>1208</sup> A Donohue (2014), “PTO Patent Examinations in the wake of Mayo and Myriad”, *Patently Biotech*, 8/12/2014.
- <sup>1209</sup> A Philippidis (2016), “Court Decisions Take a Toll on Innovation”, *Genetic Engineering & Biotechnology News*, 5/16/ 2016.
- <sup>1210</sup> See: United States Patent and Trademark Office 37 CFR Part 1 [Docket No. PTO–P–2014–0058] 2014 Interim Guidance on Patent Subject Matter Eligibility, Federal Register / Vol. 79, No. 241 / Tuesday, December 16, 2014 / Rules and Regulations.
- <sup>1211</sup> USPTO (2016), “Subject Matter Eligibility Examples: Life Sciences”, May 2016, <http://www.uspto.gov/sites/default/files/documents/ieg-may-2016-ex.pdf>
- <sup>1212</sup> PharmaPatents (2016), “USPTO Issues New Patent Eligibility Examples”, 5/6/2016, <https://www.pharmapatentsblog.com/2016/05/06/uspto-issues-new-patent-eligibility-examples/>
- <sup>1213</sup> USA Today (2016), “Obama signs trade secrets bill, allowing companies to sue”, 5/11/2016, <http://www.usatoday.com/story/news/politics/2016/05/11/obama-signs-trade-secrets-bill-allowing-companies-sue/84244258/>
- <sup>1214</sup> See for example D Torstensson and M Pugatch (2010).
- <sup>1215</sup> US FDA (2016), “Novel Drugs Summary 2015”, January 2016, <http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm474696.htm>
- <sup>1216</sup> USDA, “Biotechnology Regulatory Services/Permits, Notifications, and Petitions/Petitions, Petition Process Improvements”, (Accessed May 2016), [http://www.aphis.usda.gov/wps/portal/aphis/ourfocus/biotechnology?1dmy&urile=wcm%3apath%3a%2Faphis\\_content\\_library%2Fsa\\_our\\_focus%2Fsa\\_biotechnology%2Fsa\\_permits\\_notifications\\_and\\_petitions%2Fsa\\_petitions%2Fct\\_pet\\_proc\\_imp](http://www.aphis.usda.gov/wps/portal/aphis/ourfocus/biotechnology?1dmy&urile=wcm%3apath%3a%2Faphis_content_library%2Fsa_our_focus%2Fsa_biotechnology%2Fsa_permits_notifications_and_petitions%2Fsa_petitions%2Fct_pet_proc_imp)
- <sup>1217</sup> Ibid.
- <sup>1218</sup> S. Shane, (2004), “Encouraging University Entrepreneurship? The Effect Of The Bayh-Dole Act On University Patenting In The United States”, *Journal of Business Venturing*, 19, pp. 127-151. See introduction to this article for a full discussion of the academic debate over the effects of Bayh-Dole.
- <sup>1219</sup> L Pressman et al (2015), “The Economic Contribution of University/Nonprofit Inventions in the United States: 1996-2013”, *BIO* 2015, p. 3.
- <sup>1220</sup> Ibid.
- <sup>1221</sup> AUTM, “Highlights of AUTM’s U.S. Licensing Activity Survey FY2014” (Accessed May 2016), <http://www.autm.net/resources-surveys/research-reports-databases/licensing-surveys/fy-2014-licensing-survey/>
- <sup>1222</sup> B. Huggett (2015), “Top US Universities And Institutes For Life Sciences In 2014”, *Nature Biotechnology*, 10/22/2015, <http://www.nature.com/bioent/2015/151001/full/bioe.2015.11.html>.
- <sup>1223</sup> Ibid.
- <sup>1224</sup> NSF, “NSF Innovation Corps” (accessed May 2016), [https://www.nsf.gov/news/special\\_reports/i-corps/](https://www.nsf.gov/news/special_reports/i-corps/)
- <sup>1225</sup> Legal Information Institute, Cornell University, “26 U.S. Code § 41 - Credit for increasing research activities” (Accessed May 2016), <http://www.law.cornell.edu/uscode/text/26/41>
- <sup>1226</sup> Science (2016), “Updated: Budget agreement boosts U.S. Science”, 12/18/2015, <http://www.sciencemag.org/news/2015/12/updated-budget-agreement-boosts-us-science>
- <sup>1227</sup> Manufacturing.net (2016), “The New R&D Tax Credit: A Game-Changer For Manufacturers”, 3/10/2016, <http://www.manufacturing.net/blog/2016/03/new-r-d-tax-credit-game-changer-manufacturers>
- <sup>1228</sup> Center Watch (2015), “New Legislation Would Extend R&D Tax Credit To CROs”, 6/1/2015, [https://www.google.se/search?q=R%26D+credit+CROs+COMPETE+US&ie=utf-8&oe=utf-8&client=firefox-b-ab&gfe\\_rd=cr&ei=-5jV8eOB4mr8wfDzIGQAQ](https://www.google.se/search?q=R%26D+credit+CROs+COMPETE+US&ie=utf-8&oe=utf-8&client=firefox-b-ab&gfe_rd=cr&ei=-5jV8eOB4mr8wfDzIGQAQ)
- <sup>1229</sup> Elizabeth Pringle/EY (2015), “Pharmaceutical R&D Tax Incentives” (accessed June 2016), <http://www.ey.com/GL/en/Industries/Life-Sciences/EY-pharmaceutical-r-d-tax-incentives>
- <sup>1230</sup> TriMerit, “R&D Tax credits” (accessed May 2016), [http://www.trimerit.net/tax\\_credits/states\\_offering\\_credits.aspx](http://www.trimerit.net/tax_credits/states_offering_credits.aspx)
- <sup>1231</sup> Ross De Vol, Kristen Harris and Minoli Ratnatunga /Milken Institute (2015), “California Innovation Based Economy – Policies To Maintain And Enhance It”, p.50, 12/1/2015, California Healthcare Institute (2011), p.18.; TPA, “Tax Credit Massachusetts” (accessed May 2016), <http://www.taxpointadvisors.com/rd-tax-credit-massachusetts/>; Maryland Department of Business and Economic Development, Research and Development Tax Credit (accessed May 2016), <http://commerce.maryland.gov/fund/programs-for-businesses/research-and-development-tax-credit>
- <sup>1232</sup> US Department of Commerce/International Trade Administration, “Pharmaceutical Price Controls in OECD Countries: Implications for US Consumers, Pricing, Research and Development and Innovation” (accessed May 2016), <http://www.ita.doc.gov/td/chemicals/drugpricingstudy.pdf>
- <sup>1233</sup> World Justice Project, (2015).